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Tuberculosis  
 
Tuberculosis (TB) is a global public health emergency ranking as a 
leading cause of death from a single infectious agent worldwide, second 
only to Acquired Immune Deficiency Syndrome (AIDS). 
According to a World Health Organization report, in 2012 there were 
almost 9 million new TB cases and 1.3 million TB deaths. Most of the 
estimated number of cases in 2012 occurred in Asia (58%) and Africa 
(27%); a smaller proportions of cases occurred in the Eastern 
Mediterranean Region (8%), the European Region (4%) and the Region 
of the Americas (3%) (Figure 1) (1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1- Estimated TB incident rates, 2012 (1). 
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The majority of TB cases and deaths occur in underdeveloped countries, 
mainly due to less health care access as well as exposure to unhealthy 
living condition, malnutrition, HIV infection, homelessness, alcohol 
misuse and drug consumption (2). 
TB is an airborne disease caused by Mycobacterium tuberculosis 
(MTB), the tubercle bacillus; although MTB can infect almost any tissue 
or organ of the body, most commonly the disease results in a chronic, 
spreading lung infection that, in untreated cases, leads to progressive 
destruction of the lung tissue (3). 
At present anti-mycobacterial chemotherapy consists in a combination 
of different drugs; however, treatments outcomes are far from 
satisfactory. Long-term therapy makes patient’s compliance one of the 
most difficult issue to overcome for chemotherapy success. The coupling 
of noncompliance with the nature of MTB’s infectious process itself, 
resulted in widespread emergence of multi-drug and extensively-drug 
resistant MTB strains (MDR-TB and XDR-TB, respectively) (4). 
Treatment of MDR-TB and XDR-TB – there were approximately 0.5 
million cases in 2012 – is more challenging, requiring the use of second-
line drugs that are more expensive, cause more severe side effects, and 
must be taken for up to two years; moreover, healing rates for MDR-TB 
are lower: overall only 48% of patients were successfully treated (1). TB 
new face and the global scourge of MDR-TB and XDR-TB is reaching 
epidemic proportions. 
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Mycobacterium tuberculosis 
 
Domain: Bacteria; Phylum: Actinobacteria; Class: Actinobacteria; Order: 
Actinomycetales; family: Mycobacteriaceae; Genus: Mycobacterium 
 
Mycobacterium tuberculosis forms a complex with other closely related 
bacteria (MTB complex)  that includes several other obligate human 
pathogens, most importantly M. leprae (the etiologic agent of leprosy), 
M. africanum (common cause of TB in West-African countries 
characterized by a lower pathogenicity with respect to MTB), and M. 
bovis (the causative agent of TB in a range of animal species, mainly in 
cattle). Similarly to the other members of this genus, MTB is a large, 
non-motile, rod-shaped bacterium distantly related to the 
Actinomycetes. The bacilli are 2-4 μm in length and 0.2-0.5 μm in width. 
As an obligate aerobe MTB grows most successfully in highly 
oxygenated tissues such as the lungs and it is characterized by a slow 
growth rate (i.e. generation time of 12 to 18 hours) mainly related to the 
tough cell wall that resists to the permeation of nutrients into the cell and 
inhibits waste products to be excreted out of the cell. This peculiar  
physiological characteristic contribute to mycobacterial virulence. The 
bacterium is a facultative intracellular parasite that does not seem to fit 
the Gram-positive category from an empirical standpoint (in general, it 
does not retain well the crystal violet stain). For this reason it is classified 
as an acid-fast Gram-positive bacterium due to the lack of an outer cell 
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membrane and its unique feature to be impermeable by certain dyes and 
stains. Despite this, once stained, acid-fast bacteria will retain dyes when 
heated and treated with acidified organic compounds. The structure of 
MTB external envelope is very complex and unique among prokaryotes, 
consisting of a plasma membrane, a cell wall and a capsule-like 
outermost layer (Figure 2). By means of advanced electron microscopy 
techniques at least four layers, possessing significantly different 
properties, can been identified: i) an inner plasma membrane; ii) an 
electron-dense layer corresponding to the peptidoglycan and 
arabinogalactan coat; iii) an electron transparent zone that corresponds 
to the mycolic acid layer; and iv) an outer electron dense layer, the 
capsule-like layer (5).  
The mycolic acids assemble through powerful interactions, to form a 
lipid shell surrounding the cell (6); this feature is responsible for the 
“lipid barrier” that confers resistance to many drugs. Mycolic acids are 
threalose estherified to form threalose-6,6-dimycolate, a structure named  
“cord factor” (7) that is responsible for a unique feature of MTB known 
as “cording”; this phenomenon consists in the formation of ropelike 
tangles of laterally associated bacilli that has long been thought to be 
associated with bacterial virulence  (8).  
As supported by the identification of a porin-encoding gene, small 
hydrophilic molecules diffusion in MTB is mediated by porin-dependent 
mechanism (9).  
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Figure 2- (A) Colonies of M. tuberculosis on Lowenstein-Jensen egg-based-
medium. (B) Scanning electron microscope image of M. tuberculosis. (C) 
Mycobacterial cell wall structure (6). 
 
Transmission and pathogenesis of TB 
 
MTB is carried in airborne particles, called droplet nuclei, of 1-5 microns 
in diameter. Infectious droplet nuclei are generated when persons who 
have pulmonary or laryngeal active TB disease cough, sneeze, shout, or 
sing. Depending on the environment, these tiny particles can remain 
suspended in the air for several hours. Transmission occurs when a 
person inhales MTB-infected droplet nuclei, which then traverse the 
mouth or nasal passages, upper respiratory tract, and bronchi to reach the 
alveoli of the lungs (Figure 3). 
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Figure 3- Airborne horizontal transmission of MTB (10).  
 
The infectiousness of a person with TB disease is directly related to the 
number of tubercle bacilli expelled into the air (10); it has been estimated 
that a droplet containing 1-10 bacteria is sufficient to initiate infection, 
establishing the so called primary infection. Primary infection can be i) 
either eradicated by the host’s immune system; ii) or contained as latent 
infection; iii) or it can progress towards the active disease (11) that 
typically develops and spreads as caseating granulomas to regional 
lymph nodes (Figure 4). When the host’s immune response and MTB 
virulence are in balance, MTB is contained at the primary site of 
infection by the immune cells. Subsequently to phagocytosis of MTB 
bacilli by alveolar macrophages, lymphocytes and in particular T-cells, 
are recruited to the infected site, processing and presenting MTB antigen 
to Major Histocompatibility Complex Class II (MHC II). This results in 
T-cell activation and release of cytokines, including Interferon Gamma 
(IFN-γ), that activate macrophages recruited to the site of infection. 
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MTB is able to survive and replicate inside macrophages. The ability of 
pathogenic mycobacteria to adapt to the hostile environment of 
macrophage has been instrumental in their success as pathogens. Once 
inside the macrophages MTB interferes with the host intracellular 
trafficking pathways by modulating events in endosomal/phagosomal 
maturation pathway to create a protected niche for itself: the 
mycobacterial phagosome (12).  Phagocytosed pathogens experience 
increasing acidification, highly reactive oxidative and nitrosative species 
(ROS and RNS), hydrolytic enzymes and cationic antimicrobial peptides 
(13). ROS and RNS - generated by the phagosomal enzymes NADPH 
phagocyte oxidase and inducible nitric oxide synthase (iNOS) - damage 
captured microbes by modification of their DNA, lipids, proteins and 
active centers of metal-dependent proteins (14). The final step of 
bacterial destruction and clearance requires phagolysosome fusion. 
Pathogenic mycobacteria have evolved a unique strategy to survive 
intracellularly within macrophages: they modulate phagosome 
maturation to prevent the fusion with lysosomes (15). The block of 
phagolysosome biogenesis plays a central role in the pathogenesis of 
mycobacteria. By blocking its delivery to lysosomes, MTB is able to 
avoid the acidic proteases of the lysosomes, to avoid exposure to the 
bactericidal mechanisms that operate within lysosomes, preventing 
degradation and hence processing and presentation of mycobacterial 
antigens to the immune system (16).  
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Figure 4- Overview of the MTB infection in humans (4).  
 
Granuloma 
 
A peculiar histopathologic trait of mycobacterial infection is the 
formation of granuloma. This structure is maintained and stabilized by 
events mediated by both the host and the pathogen. It is beneficial for 
the host as it helps to contain the infection to localized regions. On the 
other hand, bacteria can live for prolonged time within the granuloma 
(16), while the bacterial spreading to other areas of the organism is 
restricted (17). The tuberculosis granuloma is a compact, organized 
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aggregate of epithelioid macrophages that have undergone a specialized 
transformation to have tight contacts with adjacent cell membranes. 
Bacteria are most commonly present in the central necrotic areas in 
which dead and dying macrophages can be detected. Many other cell 
types also populate the granuloma, such as neutrophils, dendritic cells, 
B and T cells, natural killer (NK) cells, fibroblasts and cells that secrete 
extracellular matrix components (Figure 5) (18). 
 
 
Figure 5- Structure and cellular constituents of the tuberculosis granuloma (18). 
 
In humans, the granuloma shows a high plasticity and three major types 
can be distinguished. These are solid granulomas, characteristic of the 
containment phase of the infection; necrotic granulomas, typical for 
early stages of active TB; and caseous granulomas during end-stage or 
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severe TB. These different stages are not distinct entities but form a 
continuum.  
Unfavourable conditions inside the granuloma, such as nutrient 
limitation and low oxygen tension, trigger the metabolic downshift of 
subpopulations of MTB to dormancy (11). 
Since the central region of granuloma does not contain blood vessels, it 
becomes hypoxic (19) and it has been demonstrated that hypoxia leads 
to DNA damage (20) with several DNA repair genes undergoing 
changes in their expression profile (21). 
When tubercle bacilli overcome the immune system and multiply, it 
results in progression from latent TB infection (LTBI) to TB disease that 
represents the active phase of the disease. Persons who have TB disease 
are usually infectious and may spread the bacteria to other people. The 
progression from LTBI to TB disease may occur at any time, from soon 
to many years later after infection. 
 
Chemotherapy and mycobacterial evolution 
 
Since the control measures for TB, such as Bacillus-Calmette-Guèrin 
vaccination and chemoprophylaxis, appear to be unsatisfactory, 
treatment with anti-tubercular drug represents the only option available. 
Long-term treatment with specific combination of antitubercular drugs 
is required (22). As indicated by WHO guidelines (23) treatment of TB 
and drug-resistant cases requires: 
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1- An initial intensive phase consisting in the administration of 
rifampicin (RIF), isoniazid (INH) and pyrazinamide (PYZ), and 
ethambutol (ETB) daily for two months 
2- A continuation phase consisting in administration of RIF and INH 
for a further four months, either daily or three times per week.  
INH eradicates most of the rapidly replicating bacilli in the first two 
weeks of treatment, together with ETB. Thereafter, RIF and PYZ have 
an important role in the sterilisation of lesions by eradicating the 
microorganisms; these two drugs are crucial for successful six-month 
treatment regimens. RIF kills low or non-replicating bacteria and the 
high sterilising effect of PYZ serves to act on semi-dormant bacilli 
located in sites resistant to the penetration and action of the other anti-
TB drugs (24). Anti-TB drugs sites of action are showed in Figure 6. 
Selective antibiotics promote the occurrence of mutations in the 
pathogen's genome that could lead to drug-resistance (25). Consistent 
with these findings is the occurrence of drug-resistant strains of MTB, 
which have been divided into two main groups: i) the multi-drug 
resistant (MDR) strains that are resistant to two front line drugs, 
isoniazid and rifampicin, and they cover 5.3% of all new cases of TB 
worldwide (26); and the extensively drug resistant (XDR) strains that are 
resistant to isoniazid and rifampicin plus one of the fluoriquinolones and 
at least one second-line injectable drug (amikacin).  
Without any evidence about MTB plasmids (27) or other functional 
apparatus, it is believed that drug resistance determinants are 
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chromosomally encoded and they are the consequence of spontaneous 
mutations (28) or gene inactivation by a mobile genetic element (29). 
 
Figure 6- Sites of action of the anti-TB drugs (24). 
 
As in all organisms, DNA repair systems directly influence the rates and 
types of mutation in mycobacteria. When they perform properly their 
function, these systems keep mutation rates at a low level, althought in 
several circumstances they can increase the prevalence of specific types 
of mutations. Indeed, DNA repair systems might not be efficient enough 
in repairing large amounts of DNA damage, which can therefore lead to 
mutations; secondly, some DNA damage repair systems are inherently 
error-prone, possibly introducing mutations during their action; finally, 
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mutated DNA repair proteins can lead to an increased mutation rate, as 
has been observed upon gene deletions experiments resulting in the 
absence of key enzymes in DNA repair systems of MTB (4). 
 
DNA repair in M. tuberculosis 
 
At all stages of its complex life cycle MTB is exposed to several physical 
and chemical potential DNA-damaging stresses. Before establishing a 
primary infection mycobacteria must survive inside the aerosol droplets 
in which survival rate falls to 50% after six hours (30). They experience 
both desiccation and UV radiation, possibly resulting in DNA damage; 
in fact it has been demonstrated that intracellular dehydration leads to 
double-strand breaks of DNA (31); moreover, UV radiation induces 
pyrimidine dimers as photoproducts. Subsequently to inhalation of MTB 
droplets by a healthy individual, mycobacteria continue to be exposed to 
DNA damaging assaults consisting in both oxidative and nitrosative 
stresses generated by the activated macrophages (32), leading to DNA 
alkylation through N-nitrosoamines formation (33). As described above, 
in the last stage of its life MTB survives in the granulomatous tissue 
characterized by a hypoxic environment as well as starvation, two 
conditions strictly related to DNA damage (34) (35). As also suggested 
by the induction of key enzymes involved in prevention and repair of 
DNA damage during in vitro stationary phase, mycobacteria survival in 
the dormant phase could be related to a proper deployment of DNA 
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repair systems (4). The slow-growing feature of MTB makes 
investigations on DNA repair machineries more difficult compared to 
other bacteria. As a result, most assumptions about MTB DNA repair are 
still based on homology rather than on functional studies (36). Genes 
encoding proteins involved in nucleotide excision repair (NER), base 
excision repair (BER), recombinational and SOS repair have been 
identified in MTB genome (Table 1). In particular, a full set of genes 
known to be directly involved in the repair of oxidative and alkylation 
damage are present in MTB. In contrast, homologs of gene involved in 
mismatch repair (MMR) have not been detected (37). As observed in 
Helicobacter pilory, missing MMR repair system could potentially 
contribute to a high level of genetic diversity (38); in contrast MTB 
display a remarkably low level of genetic diversity among isolates (39), 
signalling that the other systems could compensate for this lack.  
DNA repair pathway Repair strategy 
Base excision repair (BER) Removal of small, non-helix-distorting base 
lesions from the genome. 
Nucleotide excision repair 
(NER) 
Removal of short single-stranded DNA segment 
that contains bulky helix-distorting lesions 
Recombinational repair Repair of chromosomal site-specific double-
strand breaks. In homologous recombination, a 
second intact copy of the broken segment serves 
as a template for DNA synthesis. Non-
homologous end joining operate when only one 
chromosomal copy is available. 
SOS repair and mutagenesis The SOS response is a global response to DNA 
damage in which the cell cycle is arrested and 
DNA repair and mutagenesis are induced. It is 
an error-prone system. 
 
Table 1- MTB multi-step DNA repair pathways. 
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Figure 7- Major DNA repair pathways in MTB, [adapted from (37)] 
 
Alkylation damage and the Ada operon in MTB 
 
MTB is expected to sustain significant levels of nitrosative and oxidative 
stresses that form potent DNA alkylating compounds during the 
infection process (4). Alkylation damage is both genotoxic and pro-
mutagenic. Similarly to what observed in other organisms MTB can 
repair alkylated DNA by using multi-enzymatic systems (i.e. Nucleotide 
Excision Repair and Base Excision Repair whose mechanisms are 
summarized in table 1 and Figure 7) or by mounting an adaptive 
response, (Ada response) (40,41). 
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In Escherichia coli four genes are induced by Ada response: ada, alkA, 
alkB and aidB. In this system the methyltransferase AdaA acts as a 
positive regulator of the operon; AlkA is a 3-methyladenine DNA 
glycosylase whose expression level is 10-fold increased after exposure 
to sublethal doses of alkylating agents; the AlkB protein is Fe-(II)-
dependent dioxygenase responsible for the repair of 1-methyladenine 
and 3-methylcytosine; finally AidB is a DNA binding protein predicted 
to catalyze direct repair of alkylated DNA (44). 
E. coli Ada consists of two different domains: the N-terminal domain 
displaying an “AdaA” fold and the C-terminal domain displaying an  
AdaB fold. The 20 kDa AdaA domain demethylates  innocuous 
methylphosphotriesters in DNA by methyl transfer on to the cysteine 
residue of its active site (i.e. cysteine at position 38). Self-methylation 
converts Ada into a transcriptional activator with high DNA binding 
affinity to genes containing the ada operator sequence in their promoter, 
including the ada gene itself (42,43). The 19 kDa AdaB domain  acts as 
an O6-alkylguanine DNA alkyltransferase by performing the transfer of 
alkyl groups from the mutagenic and cytotoxic bases O6-methylguanine 
(O6-meG) and O4-methylthymine (O4-meT) to a strictly conserved 
cysteine of its active site (i.e. cysteine at position 321). 
Genome wide sequencing revealed that the genes coding for players of 
the Ada response are highly conserved, although characterized by 
different domain combinations and genomic organization in different 
bacterial species. In MTB, a fusion of adaA with alkA constitutes an 
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operon with the adaB gene encoding an O6-methylguanine DNA 
methyltransferase (Figure 8) (44). Searches in genome databases reveal 
that the AdaA-AlkA fusion seems to be as common as AdaA with AdaB 
in bacteria (42). 
Yang et al. have recently characterized the ada operon of MTB by 
biochemical analysis and functional complementation assays. Activity 
assays with purified recombinant proteins demonstrated that both AdaA-
AlkA and AdaB possess DNA methyltransferase activity, whereas no 3-
methyladenine DNA glycosylase activity could be detected. 
Furthermore, trans-complementation of an OGT-defective E.coli strain 
(KT233) with MTB adaB gene rescues the hypermutator phenotype 
while the expression of the MTB AdaA-AlkA in the same system does 
not produce the same effect. These results suggest that in MTB AdaB 
counteracts the mutagenic effect of O6-meG, thus behaving as a genuine 
O6-methylguanine DNA methyltransferase (OGT), whereas AdaA-AlkA 
possesses a methyltransferase activity that removes methyl groups from 
innocuous methylphosphotriesters (44). 
 
Figure 8- Schematic representation of chromosomal organization of the Ada response 
genes in E.coli and structural homologs in MTB (44). 
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MTB mutant strains lacking the ada operon, including adaA-alkA and 
adaB/ogt showed a 100-fold increase in mutation frequency as compared 
to wild-type cells after treatment with the alkylating agent N-methyl-N′-
nitro-N-nitrosoguanidine (MNNG). Moreover this mutant displayed 
hypersensitivity to MNNG comparable to that of adaB/ogt-defective 
E.coli strains (45). Analyzing the phenotypic effect of the absence of ada 
operon, mice infected with wild type and mutant MTB strain did not 
show significant differences in bacillary loads present in the lungs, liver, 
and spleen, when they were measured at a relatively early stage of 
stationary infection. Therefore it has been proposed that in MTB the Ada 
response to alkylation damage is restricted to counteract mutagenesis 
without producing any evident effect onto mycobacterial viability in vivo 
(44, 45). These findings lead to the hypothesis that a defective Ada 
response in mutant MTB strains could produce a selective advantage in 
terms of adaptation to the human host and environmental changes. 
Notably, the analysis of MDR W-Beijing strains revealed that nine out 
of fiftyfive analysed strains had nonsynonymous single-nucleotide 
polymorphisms (nsSNP) on codon 37 of the OGT-encoding gene, 
leading to the Arg to Leu substitution (R37L). nsSNP on codon 15, 
leading to Thr to Ser substitution was observed in twentyfour of 
twentynine strains of the Harlem family (46). Further sequencing of the 
ada operon of hundreds Central African Republic (CAR) MDR and non-
MDR MTB strains revealed other SNPs in their Ada operon genes (47) 
(Figure 9 and 10), suggesting that certain MTB strains characterized by 
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a defective DNA-alkylation repair could be particularly prone to acquire 
mutations that may result in drug resistance and in a better adaptation to 
the host. 
 
 
Figure 9- Characteristics of MDR W-Beijing strains originating from different 
countries (46). 
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Figure 10- Characteristics of MTB strains from Harlem family originating from 
different countries (46). 
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Structural and functional aspects of alkylated-
DNA repair enzymes 
 
As mentioned above, the alkylation of exocyclic oxygens of the DNA 
nitrogen bases, and in particular the O6 position of guanine and to a lesser 
extent the O4 position of thymine are promutagenic. While alkylation at 
the O6 position of guanine typically constitutes a small fraction of the 
damage produced by exogenous alkylating stresses, it is principally 
responsible for the GC→AT transition mutations associated with 
mutagenic effects of many alkylating agents (48). 
Alkylguanine-DNA alkyltransferases (AGT) are evolutionary conserved 
DNA repair proteins that represent the main cellular mechanism 
responsible for  alkylguanine repair. 
All members of this protein family described till now (including the 
mycobacterial O6-methylguanine-DNA  methyltransferase),  invariably 
act through a suicidal mechanism by performing the stoichiometric 
transfer of the O6-alkyl group from the modified base to a strictly 
conserved cysteine buried in their active site (a SN2-like reaction) 
(Figure 11) (49), resulting in a permanently inactivated protein probably 
addressed  to degradation (50, 51).  
Sequences encoding AGTs are readily recognized in genomic data bases 
since virtually all AGT proteins contain the consensus sequence -
(I/V)PCHR(V/I)(I/V)- surrounding the cysteine residue that serves as the 
alkyl acceptor. 
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Figure 11- Reaction mechanism of human AGT by activation of catalytic cysteine 
via interaction with glutamate-histidine-water-cysteine (49). 
 
These proteins, which consist of a small single polypeptide chain, have 
been found in most bacteria, archea, fungi and animals but not in plants. 
Notably, an AGT ortolog is also absent from the fission yeast 
Schizosaccharomyces pombe (49). Structural studies (52, 53, 54, 55, 56, 
and 57) revealed that these proteins show a similar overall structure 
despite limited sequence identity, which is restricted to the DNA binding 
domain. 
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The three-dimensional structure consists of two roughly globular 
domains connected by a loop (Figure 12). The highly structurally 
conserved C-terminal domain contains the active site pocket that houses 
the catalytic cysteine within the PCHR consensus sequence, adjacent to 
the DNA-binding Helix-Turn-Helix motif. The poorly functionally 
characterized N-terminal domain displays a low degree of primary 
sequence and structural conservation between different species. X-ray 
structures of human AGT bound to dsDNA were solved (54, 55). These 
studies revealed that the helix-turn-helix motif of the C-terminal domain 
unusually binds the DNA at the level of its minor groove. The 
recognition helix is small and contains hydrophobic residues allowing it 
to pack closely within the DNA minor groove with minimal sequence-
specificity (54, 58). The binding alter the DNA structure, bending the 
chain sugar-phosphate by about 15°, widening the minor groove and 
displacing the target modified base into the active site pocket. This 
displacement is caused by a rotation promoted by specific residues (54), 
and is stabilized by a conserved arginine finger that replaces the flipped-
out base in the regular base stacking. 
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Figure 12- Molecular architecture of human AGT (53). 
 
It is known that human AGT binds the target DNA in a cooperative 
fashion (59).  It has been proposed that cooperative binding could 
facilitate both directional scanning and the efficient repair of lesion 
contained within chromatin structure. A model, predicting quaternary 
structure topology, demonstrated that cooperative assemblies contain a 
3-start helical array of proteins with dominant protein-protein 
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interactions between the N-terminal face of protein n and the C-terminal 
face of protein n+3 (Figure 13) (59). The occluded binding-site sizes in 
cooperative complexes are significantly smaller compared to the DNA 
surface occupied by an AGT monomer, corresponding to four 
nucleotides for both double-strand and single strand DNA. As mentioned 
above, differently from other helix-turn-helix DNA binding proteins, 
AGT interacts with DNA through a minor groove-binding mechanism. 
It is well know that major groove binding allows base-specific hydrogen 
bonds and seems optimal for sequence-specific recognition, whereas the 
DNA minor groove binding performed  by AGT seems advantageous for 
both sequence-independent binding and nucleotide flipping (54). 
Considering substrate specificity, competition studies with 
oligodeoxynucleotides containing O6-benzylguanine (O6-bG) and O6-
meG in the same sequence clearly showed that O6-bG is the preferred 
substrate for mammalian OGTs, that E. coli OGT has no preference and 
E. coli Ada-B greatly prefers O6-meG (60). Finally, it is fully established 
that the DNA adduct, O4-methylthymine, which is a very minor product 
of the reaction of DNA with methylating agents, can also be repaired by 
OGTs from different species, althought at different rates (61). 
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Figure 13-A model of human OGT-DNA quaternary structure resulting in a three-
start helical array. [Adapted from (59)]. 
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Outline of the thesis 
 
Tuberculosis is a global health emergency with nearly 1.5 million deaths 
that occur annually and more than two billion people currently infected 
with TB bacilli. As a facultative intracellular pathogen, Mycobacterium 
tuberculosis (MTB), the etiologic agent of TB, survives and replicates 
inside the human macrophages. Accordingly, during its entire life cycle 
MTB is exposed to a variety of DNA-damaging stresses including 
alkylating agents that may compromise both persistence in the host’s 
infected macrophages as well as the reactivation of the bacillus from the 
dormant state. 
Similarly to what observed in other organisms MTB attains alkylated-
base repair, maintaining its genome integrity and a low level of genetic 
variability, either by using multi-enzymatic repair systems or by direct 
removing the alkyl group from the damaged base sacrificing one 
molecule of a DNA-protein alkyltransferase such as O6-methylguanine 
methyltransferase (OGT). Notably, a number of geographically widely 
distributed MTB W-Bejing strains and multi-drug resistant (MDR) 
isolates show nonsynonymous SNPs in their OGT encoding sequence 
resulting in amino acid substitutions at the poorly functionally 
characterized N-terminal domain of the enzyme (T15S and R37L). 
MDR-TB is reaching epidemic proportions and DNA repair systems is 
supposed to play a main role in MDR strains occurrence as well as in 
mycobacterial pathogenesis. For this reason biochemical and structural 
  Chapter 2 
38 
 
investigations on O6-methylguanine DNA methyltransferase and 
mutated versions mimicking the ones occurring in clinical isolates could 
provide new insights on hypermutator phenotype genesis in vivo as a 
consequence of catalytic defects in alkylated DNA repair. 
Moreover, the improved understanding of MTB DNA repair 
mechanisms may allow to reveal biochemical details of the 
mycobacterial life cycle that could be integrated in the complex 
framework describing the MTB systems biology.  
In the chapter three of the present PhD dissertation, I report on the kinetic 
analysis and structural characterization of MTB OGT and point-mutated 
variants designed to mimic the mentioned SNPs, in order to explore the 
functional effects of these mutations. Biochemical studies reveal that 
these amino acid substitutions affect, to different extents, alkyl-guanine 
repair activity suggesting a new role of the N-terminal domain of the 
protein in the coordination of the catalytic cycle and/or in mediating 
protein cooperative assembly at damaged DNA sites. As described in 
chapter four we extended this analysis to other mutants in order to better 
describe the structural and functional elements of novelty displayed by 
MtOGT when compared to other ligand-free or DNA-bound OGT 
models. Overall, the results discussed in this thesis provide experimental 
evidence of a possible contribution of a defective alkylated DNA repair 
to the “mutator” phenotype proposed for several MDR MTB strains. 
 
 
  Chapter 2 
39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 3 
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 3 
41 
 
Biochemical and Structural Studies of the Mycobacterium 
tuberculosis O6-Methylguanine Methyltransferase and 
Mutated Variants 
 
Riccardo Miggianoa*, Valentina Casazzaa*, Silvia Garavagliaa, Maria 
Ciaramellab, Giuseppe Peruginob, Menico Rizzia, Franca Rossia. 
 
aDipartimento di Scienze del Farmaco, University of Piemonte Orientale 
A.Avogadro,Novara,Italy; bIstituto di Biochimica delle Proteine, IBP-CNR 
 
Published in Journal of Bacteriology, June 2013; 195 (12): 2728–2736. Epub 5 April 
2013 
 
Summary 
 
Mycobacterium tuberculosis displays remarkable genetic stability 
despite continuous exposure to the hostile environment represented by 
the host’s infected macrophages. Similarly to other organisms, M. 
tuberculosis possesses multiple systems to counteract the harmful 
potential of DNA alkylation. In particular, the suicidal enzyme O6-
methylguanine-DNA methyltransferase (OGT) is responsible for the 
direct repair of O6-alkylguanine in double-stranded DNA and is 
therefore supposed to play a central role in protecting the mycobacterial 
genome from the risk of G·C-to-A·T transition mutations. Notably, a 
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number of geographically widely distributed M. tuberculosis strains 
shows nonsynonymous single-nucleotide polymorphisms in their OGT-
encoding gene, leading to amino acid substitutions at position 15 (T15S) 
or position 37 (R37L) of the N-terminal domain of the corresponding 
protein. However, the role of these mutations in M. tuberculosis 
pathogenesis is unknown. We describe here the in vitro characterization 
of M. tuberculosis OGT (MtOGT) and of two point-mutated versions of 
the protein mimicking the naturally occurring ones, revealing that both 
mutated proteins are impaired in their activity as a consequence of their 
lower affinity for alkylated DNA than the wild-type protein. The analysis 
of the crystal structures of MtOGT and MtOGT-R37L confirms the high 
level of structural conservation of members of this protein family and 
provides clues to an understanding of the molecular bases for the reduced 
affinity for the natural substrate displayed by mutated MtOGT. Our in 
vitro results could contribute to validate the inferred participation of 
mutated OGTs in M. tuberculosis phylogeny and biology. 
 
Introduction 
 
During its entire life, Mycobacterium tuberculosis is exposed to a variety 
of potential physical and chemical DNA-damaging stresses that could 
compromise the settling, containment, and reactivation of the infection 
(1). In order to maintain high genome stability, signaled by a remarkably 
low level of genetic diversity among isolates (2), it is therefore 
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mandatory for M. tuberculosis to possess efficient systems to counteract 
the effects of such environmental and host-generated DNA-endangering 
assaults (3–6). In particular, during its long-term persistence inside 
infected macrophages, M. tuberculosis must deal with endogenous 
DNA-alkylating chemical species originated by the action of highly 
reactive oxidative and nitrosative radicals (7). The majority of living 
organisms attain alkylated base repair by deploying different strategies, 
depending upon the chemical nature of the alkyl group, the entity of the 
damage, and the physiological condition of the cell: (i) the multistep 
excision of a short, lesion-containing strand followed by new DNA 
synthesis; (ii) the substitution of the modified base in toto; or (iii) the 
direct surgical removal of the alkyl-substituting group from the base by 
sacrificing one molecule of a DNA-protein alkyltransferase (8, 9), such 
as the O6-methylguanine-DNA methyltransferase (OGT) (EC 2.1.1.63). 
All OGT members studied until now invariably act through a suicidal 
mechanism (10), by performing the stoichiometric transfer of the O6-
alkyl group from the modified guanine to a strictly conserved cysteine 
residue in the protein active site, which is hosted in the C-terminal 
domain of the protein. This covalent modification leaves OGT 
permanently inactivated and possibly more prone to degradation (11, 12) 
(Fig. 1). 
Paralleling observations of other bacteria (13), the mycobacterial OGT-
encoding sequence (adaB; Rv1316c) is part of an adaptive response 
operon, which was recently functionally characterized (14). Gene 
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inactivation experiments demonstrated that adaB (here referred to as 
OGT, in analogy to orthologs in other species) is not essential for 
infectivity and survival either in vitro or in the mouse model of M. 
tuberculosis infection (15, 16). However, several observations support 
the importance of OGT activity in protecting the mycobacterial GC-rich 
DNA from the promutagenic potential of guanine O6-methylation. First, 
the OGT gene expression profile changes during infection and in 
response to alkylating compounds (14, 17, 18), signaling a requirement 
for fine-tuned OGT modulation under stressful conditions; moreover, the 
heterologous expression of M. tuberculosis OGT (MtOGT) in the 
Escherichia coli KT233 ada-ogt-defective strain suppresses its MNNG 
(N-methyl-N’-nitro-N-nitrosoguanidine) sensitivity (14) and rescues the 
hypermutator phenotype.  
Interestingly, two nonsynonymous single-nucleotide polymorphisms 
(nsSNPs) have been identified in the OGT genes of both M. tuberculosis 
Beijing strains and multidrug-resistant isolates (19–21), leading several 
authors to postulate that corresponding mutated OGTs may contribute to 
the success of these strains in terms of worldwide distribution; indeed, it 
has been suggested that a defective OGT might result in an increased 
mutation frequency and, thus, in a better capability of the bacterium to 
rapidly adapt to the host (14, 19). Notably, both these nsSNPs result in 
amino acid substitutions at the poorly structurally conserved and 
functionally characterized N-terminal domain of OGT, thus limiting the 
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possibility of predicting their effect on protein activity exclusively based 
upon preexisting information.  
 
Figure 1 Schematic representation of transfer of O6-alkyl group from modified 
guanine to strictly conserved cysteine in the protein active site. 
 
Many years of intense investigations rendered a detailed picture of the 
catalytic mechanism used by these proteins as well as of the structural 
elements of the   C-terminal domain playing essential roles in DNA 
binding and alkyl group removal (8, 10); in contrast, a more limited 
number of studies put the focus onto the N-terminal domain, which could 
play a role in the coordination of the catalytic cycle (22) and/or in 
mediating protein assembly at the site of damage upon DNA binding 
(23–25). 
In the present work, we exploited a recently described fluorescence-
based approach (26) to analyze the kinetics of the reaction performed by 
wild-type MtOGT and by two point-mutated variants of the protein 
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mimicking the ones occurring in M. tuberculosis clinical isolates (i.e., 
MtOGT-R37L and MtOGT-T15S). The method relies on the use of a 
fluorescent derivative of O6-benzylguanine, an inhibitor of human O6-
alkylguanine-DNA alkyltransferase (AGT), and allows the dissection of 
the OGT reaction in its DNA binding and alkylguanine transfer steps, 
thereby leading to the determination of the DNA binding affinity and the 
alkyltransferase reaction rate. 
The results of our biochemical studies reveal that although neither 
mutation affects the intrinsic alkyl-guanine-transferase reaction rate, 
both variants display reduced DNA binding affinity although to different 
extents, with MtOGT-R37L showing a 10-fold-lower affinity for 
alkylated double-stranded DNA (dsDNA) than the wild-type protein. 
Moreover, the crystal structures of MtOGT and its R37L mutant reported 
here give a contribution to the overall description of this structurally 
conserved class of proteins and provide a framework to investigate the 
possible molecular bases of the observed  DNA binding defect. 
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Materials and method 
 
Chemicals. All reagents were obtained from Sigma-Aldrich unless 
otherwise specified. 
Construction of expression vectors. The open reading frame coding for 
M. tuberculosis O6-methylguanine methyltransferase (Rv1316c) was 
isolated by PCR using the clone MTCY130 (Institute Pasteur, Paris, 
France) as the template, the Hot-Star PCR system (Qiagen), and primers 
MtOGTfwd and MtOGTrev (see Table S1 in the supplemental material). 
The NcoI-BamHI double-digested PCR product was then ligated into the 
similarly digested pET16b vector (Novagen) by standard techniques 
(27), resulting in the pET-MtOGT construct. Plasmids encoding the 
T15S and R37L point mutants of MtOGT (pET-MtOGT-T15S and pET-
MtOGTR37L) were obtained by using the pET-MtOGT construct as the 
DNA template, the two primers pairs T15Sfwd/T15Srev and 
R37Lfwd/R37Lrev (see Table S1 in the supplemental material), and the 
QuikChange II site-directed mutagenesis kit (Stratagene). In each 
construct, the region encoding the wild-type protein or its point-mutated 
variant was verified by sequencing (Eurofins MWG Operon). 
Expression and purification of wild-type MtOGT and point mutants. 
The following procedure was invariably used to express and purify the 
wild-type protein and the relative point-mutated versions used in 
biochemical analyses. E. coli strain BL21(DE3) bacteria (Novagen), 
freshly transformed with one of the three expression constructs, were 
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spread onto LB agar plates with 50 µg/ml ampicillin and grown at 37°C 
overnight. The next day, colonies were scraped and inoculated in 1 liter 
of selective ZYP- 5052 medium (28) to reach a starting optical density 
at 600nm (OD600) of 0.1. This culture was further grown at 37°C for 3 h 
and then brought to 17°C for 16 h with vigorous shaking to autoinduce 
the expression of the recombinant protein. A bacterial pellet was 
obtained by centrifugation (11,000 ×g for 15 min at 4°C), washed once 
in phosphate-buffered saline (PBS), dissolved in 50 ml of buffer A (20 
mM Tris-HCl, pH 7.8), and disrupted by ultrasonication. Upon the 
addition of a protease inhibitor cocktail, the insoluble material of the 
lysate was removed by centrifugation (14,000 ×g for 45 min at 4°C), and 
the recombinant protein was purified from the supernatant by fast protein 
liquid chromatography (FPLC) (Akta Basic Instrument; GE Healthcare), 
using, in sequence, HiTrapQ, MonoQ, HiTrap heparin, and Superdex 
200 prepacked chromatography media (GE Healthcare), as further 
detailed in the supplemental material (see Fig. S1 in the supplemental 
material). During the entire procedure, the recombinant protein was 
monitored by standard SDS-PAGE analysis (29), and the protein 
concentration was determined by the Bradford assay (30), using bovine 
serum albumin as the standard. 
Activity assays. To measure the alkyltransferase activity of wild-type 
MtOGT and relative mutants, a fluorescence assay using SNAP-Vista 
Green reagent (New England BioLabs) (here referred to as VG for 
brevity) was used, as previously described (26) (see Fig. S2A in the 
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supplemental material). Protein bands from SDS-PAGE were visualized 
by direct gel imaging (VersaDoc 4000; Bio-Rad), and their fluorescence 
intensities (FIs), corresponding to the reacted protein, were corrected for 
the actual amount of protein loaded into each lane by measuring the 
intensity of bands after Coomassie brilliant blue R250 staining. Activity 
assays at different pH values were performed with 1× Fluo reaction 
buffer containing 50.0 mM different buffering species, allowing the 
determination of the pH optimum of the reaction used in all subsequent 
experiments (data not shown). 
Enzyme kinetics analysis. Assuming a 1:1 substrate-enzyme 
stoichiometry and irreversible binding, incubation of a fixed amount of 
protein (5.0 µM) with VG (in the range of 0.1 to 20.0 µM) for 1 h at 
25°C gave corrected FI data, which were fitted by a linear equation 
whose slope gave a direct reference value of FI/µM protein, which was 
then used to estimate the amount of covalently modified protein 
(expressed in picomoles) in time course experiments. The latter assays 
were performed at 25°C using different protein/VG molar ratios and 
taking 10.0-µl aliquots at time intervals, as detailed in Fig. S2B in the 
supplemental material. Plots of the picomoles of reacted protein versus 
time were fitted by exponential equations to determine the apparent rates 
for covalent modification (kobs). 
These values were plotted versus the VG doses ([VG]) by using the 
following hyperbolic equation: 
                                𝑘obs   =
𝑘
1+KVG /[VG]
                                          (1) 
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Table 1 Kinetic constants of the reaction catalysed by MtOGT and mutated 
proteins. 
 ds-DNAmet 
(µM)  
Mean k (s-1) ± 
SD  
Mean KVG 
(µM) ± SD  
Mean KDNA  
(µM) ± SD 
    
0  
  
0.12 ± 0.02  
  
1.82 ± 0.4  
  
  
0.63  
 
0.14 ± 0.03  
 
3.53 ± 0.5  
 
MtOGT  1.00  
1.25  
0.10 ± 0.03  
0.14 ± 0.02  
5.29 ± 0.9  
8.68 ± 0.8  
0.24± 0.11  
 
0  
  
0.10 ± 0.01  1.73 ± 0.5  
 
  
0.63  
 
0.11 ± 0.01  
 
2.29 ± 0.4  
 
MtOGT-T15S  1.00  
1.25  
0.13 ± 0.02  
0.12 ± 0.03  
3.46 ± 0.5  
5.40 ± 0.7  
0.48 ± 0.26  
 
0  
  
0.07 ± 0.02  3.17± 0.5  
 
  
0.63  
 
0.09 ± 0.02  
 
4.23± 0.7  
 
MtOGT-R37L  
  
1.00  
1.25  
  
0.07 ± 0.01  
0.08 ± 0.02  
  
4.55± 0.6  
5.11± 0.5  
  
2.16 ± 0.23  
  
 
 
where k and KVG are the rate of covalent linkage and the dissociation 
constant for the free enzyme and free VG reagent during the first 
collision step (before covalent modification), respectively (see Fig. S2C 
in the supplemental material). In order to calculate the apparent KVG 
values (KVG
app) of proteins for VG as a function of the double-stranded 
methylated DNA (dsDNAmet) concentration, time course experiments 
such as those described above were performed in the presence of 
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increasing fixed doses of dsDNAmet (see Table S1 and Fig. S3 in the 
supplemental material). 
Data were fitted according to the following linear equation: 
 
                                KVG
      app
=
KVG 
KDNA
 [dsDNAmet]+ KVG                    (2) 
 
where KDNA is the dissociation constant of the protein for the dsDNA
met 
substrate. The results of these enzyme kinetics analyses are summarized 
in Table 1. 
Electrophoretic mobility shift assay (EMSA). A 40-bp 6-
carboxytetramethylrhodamine (TAMRA)-labeled double-stranded DNA 
probe (0.1 µM) was incubated at 25°C for 10 min with different amounts 
of proteins in the range of 0.0 to 120.0 µM in a total volume of 10.0 µl 
in 1× binding buffer (20.0 mM Tris-HCl [pH 7.5], 50.0 mM KCl, 0.1 
mM dithiothreitol [DTT], and 10% glycerol). Samples were loaded onto 
an 8% polyacrylamide-bisacrylamide native gel in 1× Tris-borate-EDTA 
(TBE). Signals were visualized by direct gel imaging using a green light-
emitting diode (LED)/605-nm-band-pass filter as excitation/emission 
parameters, respectively. 
Crystallization. Initial conditions for MtOGT crystallization were 
identified by means of a robot-assisted (Oryx4; Douglas Instruments), 
sitting-drop-based spare-matrix strategy using screen kits from Hampton 
Research. The best crystals were obtained by mixing 2 µl of a protein 
solution at 5 mg/ml with an equal volume of a reservoir solution 
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containing 0.1 M HEPES (pH 7.5), 6% (wt/vol) polyethylene glycol 
8000 (PEG 8000), and 6% (wt/vol) ethylene glycol and equilibrating the 
drop against 800 µl of the reservoir solution at 4°C in sitting-drop format. 
Crystals used in X-ray diffraction experiments grew to maximum 
dimensions of 0.2 mm in about 2 weeks. Similarly, crystallization of the 
MtOGT-R37L mutant enzyme was obtained by mixing 2 µl of the 
protein solution at 4 mg/ml with an equal volume of crystallization 
buffer (0.1 M HEPES [pH 7.5], 12% [wt/vol] PEG 8000, 4% ethylene 
glycol) and equilibrating the drop against 800 µl of the reservoir at 4°C 
in sitting-drop format, yielding 0.2-mm crystals in about 2 weeks. 
Structure determination. For X-ray data collection, crystals of both 
wild-type MtOGT and MtOGT-R37L were taken directly from the 
crystallization droplet, rapidly equilibrated in a solution containing the 
crystallization buffer and 15% glycerol as a cryoprotectant, and flash-
frozen at 100 K under liquid nitrogen. 
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Table 2 Data collection, phasing and refinement statistics 
 
 MtOGT  MtOGT-R37L  
Data collection  
Space Group  
    
P21212  P21212  
Wavelength (Å)  0.933  0.99  
Resolution (Å)  1.8  2.8  
Total reflections  70150  16209  
Unique reflections  17690  4572  
Mean(I)/sd(I)  15.8 (4.4)  10.2 (3.6)  
Completeness (%)  99.5 (100)  96.2 (100)  
Multiplicity  4.0 (4.0)  3.5 (3.6)  
Rmerge (%)  4.8 (27.2)  8.2 (31.6)  
Rmeas  (%)  5.5 (31.3)  9.4 (36.4)  
Rpim (%)  2.7 (15.3)  4.5 (17.5)  
Refinement    
Rfactor/Rfree (%)  21.8/26.4  18.6/26  
Protein Atoms  1251  1258  
Ligand atoms  19  -  
Water molecules  141  48  
R.m.s.d. bond (Å)  0.007  0.009  
R.m.s.d. angles (°)  1.016  1.151  
Average B (Å2)  
   Protein  34.3  63.4  
   Solvent  40.5  50.2  
                      Residues in Ramachandran plot areas (%) 
Preferred 96.3 98 
Allowed 3.7 2 
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A complete data set of the wild-type MtOGT crystal was collected at 100 
K to a 1.8-Å resolution using synchrotron radiation (λ= 0.933 Å) at the 
ID14-EH1 beam line (European Synchrotron Radiation Facility [ESRF], 
Grenoble, France), equipped with an ADSC detector. Analysis of the 
collected diffraction data set allowed us to assign the crystal to the 
orthorhombic space group P21212, with the cell dimensions a = 59.13 Å, 
b = 81.75 Å, and c = 38.16 Å, containing 1 molecule per asymmetric 
unit, with a corresponding solvent content of 52%. For all data 
collections, diffraction intensities were evaluated, integrated, and scaled 
by using the CCP4 suite of programs (31). The structure of MtOGT was 
solved by molecular replacement using the program Phaser (32) and the 
structure of E. coli O6-methylguanine-DNA methyltransferase AdaC 
protein as the search model (Protein Data Bank [PDB] accession number 
1SFE) (33). The resulting electron density map was of high quality and 
allowed automatic tracing by the program ARP/wARP (34), which was 
also used for adding solvent molecules. The program Coot (35) was used 
for manual rebuilding, and the program PHENIX (36) was used for 
crystallographic refinement. 
A complete data set of the MtOGT-R37L crystal was collected at 100 K 
to a 2.8-Å resolution using synchrotron radiation (λ= 0.99 Å) at the 
ESRF ID23 beam line equipped with an ADSC detector. Since the 
analysis of the diffraction data set showed the MtOGT-R37L crystal to 
be isomorphic with those of the wild-type protein, we used the refined 
set of atomic coordinates of the MtOGT protein (in which water/ligand 
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molecules and Arg37 side-chain atoms were omitted) for MtOGT-R37L 
structure determination; model building and crystallographic refinement 
were performed following the same procedure described above for the 
wild-type protein. Data collection, phasing, and refinement statistics are 
given in Table 2. Structural superpositions were performed with the 
Superpose program of the CCP4 suite (31). Figures 3 through 6 were 
generated with PyMol (37). 
Protein structure accession numbers. The atomic coordinates and 
structure factors of MtOGT and MtOGT-R37L have been deposited in 
the Protein Data Bank (http://www.rcsb.org/) under accession numbers 
4BHB and 4BHC, respectively. 
 
Result and discussion 
 
Expression and purification of wild-type and point-mutated MtOGT 
variants. In order to perform a molecular characterization of the M. 
tuberculosis OGT protein, the corresponding open reading frame was 
subcloned into the pET16b vector within the NcoI/BamHI sites of the 
polylinker to eliminate the standard polyhistidine coding region. Once 
transformed into E. coli strain BL21(DE3), the resulting pET-MtOGT 
expression construct drives the synthesis of an untagged version of the 
protein (MtOGT) (predicted molecular mass of 17,844 Da; 165 amino 
acid residues; Ile in position 2 replaced by Val as a consequence of the 
adopted subcloning strategy) that could be reproducibly purified at a 
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high yield by FPLC-based standard techniques. pET-MtOGT was also 
used as the template for PCR-based site-directed mutagenesis to generate 
the expression vectors for the production in E. coli of two point-mutated 
variants of the enzyme (MtOGTT15S and MtOGT-R37L), which mimic 
those naturally occurring in M. tuberculosis strains bearing nsSNPs at 
codon 15 (ACC mutated to AGC) or codon 37 (CGC mutated to CTA) 
of their OGT coding sequence (19–21). We obtained pure and highly 
homogeneous preparations of both MtOGT-R37L and MtOGT-T15S, 
and we observed that, similar to other OGTs, our recombinant proteins 
behave as monomers in solution (see Fig. S1 in the supplemental 
material). These observations indicate that the R37L and T15S amino 
acid substitutions do not affect the overall stability of the corresponding 
mutated proteins and do not alter their quaternary structure in the 
absence of ligands. 
Biochemical characterization of MtOGT. From a biochemical point of 
view, OGT proteins are at the same time the catalyst and one of the 
stoichiometric reagents of the alkyl group transfer from the modified 
base to the reactive cysteine (Cys126 in MtOGT) in the active site, 
resulting in permanent inactivation of the protein (10). We exploited this 
feature to characterize the kinetics of the reaction performed by MtOGT 
and its variants by adopting a recently developed procedure (26) that 
makes use of derivatives of O6-benzylguanine (a well-known inhibitor 
of AGTs), which acts by covalent transfer of the benzylic group to the 
active-site cysteine (see Fig. S2A in the supplemental material). The 
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method allows the determination of the MtOGT catalytic activity from 
the direct measurement of the covalent protein-inhibitor fluorescent 
complex. Specifically, the fluorescein-labeled O6-benzylguanine 
derivative SNAP-Vista Green (VG) was used to measure the activities 
of MtOGT, MtOGT-T15S, and MtOGTR37L by quantifying the 
intensity of the signal emitted by the VG-modified protein analyzed by 
SDS-PAGE. In all three cases, the fluorescence intensity of the band 
showed a linear dependence on the VG reagent concentration, reaching 
a plateau at a 1:1 protein/VG ratio, thus confirming the predicted 
stoichiometry and the suicide nature of the reaction catalyzed by 
MtOGT, regardless of the presence of either the T15S or R37L mutation 
(data not shown). 
Notably, this analysis also revealed that the MtOGT active site is in 
principle capable of housing bulky base adducts, as shown previously 
for the Sulfolobus solfataricus protein (26); in addition, it confirmed the 
robustness of the fluorescent VG-based assay and its applicability for the 
careful characterization of OGT proteins in general as a reliable 
alternative to classical and laborious assays for DNA-alkyltransferase 
activity. 
Time course experiments, performed with different protein/VG ratios, 
allowed us to determine the kinetic constants for the covalent 
modification of MtOGT, MtOGT-T15S, and MtOGT-R37L. The values 
obtained in the presence of the synthetic substrate VG were similar for 
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all the three proteins (Table 1), suggesting that neither mutation affects 
the alkyltransferase reaction rate. 
Previous work with the S. solfataricus OGT protein showed that the 
assay can also be applied to determine the activity of OGT proteins 
toward their natural substrate (i.e., alkylated DNA) in competition 
experiments (26). We thus repeated the time course experiments 
described above in the presence of increasing amounts of a double-
stranded DNA fragment bearing an internal O6-methylated guanine 
(dsDNAmet), which is expected to compete with the VG reagent in the 
alkyltransferase reaction. According to equation 2, a linear plot of the 
KVG values as a function of the dsDNA
met concentration (see Fig. S3 in 
the supplemental material) allowed the calculation of the dissociation 
constant (KDNA) of MtOGT and of the two point mutants for this 
substrate. Our data indicate that both mutations affect the protein affinity 
for methylated DNA albeit to different extents: whereas the MtOGT-
R37L point mutant exhibited a 10-fold-lower affinity for dsDNAmet 
(KDNA= 2.16 ± 0.23 µM) than the wild-type protein (KDNA= 0.24 ± 0.11 
µM), this difference appeared less pronounced for MtOGT-T15S (Table 
1). Thus, although neither mutation results in impaired intrinsic 
alkyltransferase activity, both MtOGT variants, and MtOGT-R37L in 
particular, exhibit reduced affinity for an alkylated DNA molecule. 
To investigate the reasons for the reduced activity of the mutated 
MtOGTs toward their physiological substrate, we studied direct protein-
DNA associations using a fluorescent dsDNA probe (see Table S1 in the 
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supplemental material) in an EMSA based analysis. Figure 2 shows that 
wild-type MtOGT binds ds-DNA in a cooperative manner with a plateau 
at a DNA/protein molar ratio of 1:150 and a dissociation constant value 
(K) of approximately 7 µM, a value comparable to that determined for 
human AGT by using the same method (38). In contrast, MtOGTT15S 
and MtOGT-R37L showed a significant reduction in dsDNA binding, 
with a plateau at DNA/protein molar ratios of 1:300 and 1:600 (K values 
of approximately 14 µM and 26 µM), respectively. 
Taken together, our data indicate that although neither mutation affects 
specifically the kinetics of the alkyl group transfer from the synthetic VG 
substrate to the protein, both mutations significantly decrease the 
protein’s capability of associating with DNA molecules and, 
consequently, the protein’s ability to efficiently perform alkylated-DNA 
repair. To assess whether this catalytic defect translates in vivo into a 
“hypermutator” phenotype, possibly beneficial to the fitness of the 
bacillus under circumstances of selective pressure, will require further 
microbiological studies. 
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Figure 2 DNA binding activity of wild-type MtOGT and point-mutated proteins. (A) 
Band shift analysis of MtOGT (wild type [WT]), MtOGT-T15S (T15S), and MtOGT-
R37L (R37L) proteins. Lane 1, 1 pmol of fluorescent double-stranded DNA probe 
(DNA); lanes 2 to 9, increasing amounts of protein (P) incubated in the presence of 
the probe at the indicated DNA/protein molar ratios. The white and black arrowheads 
point to the free and protein-bound probes, respectively. (B) Plot of the DNA-bound 
protein fractions at the DNA/protein molar ratios indicated in panel A. K, 
dissociation constant (µM). 
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Structural analysis of MtOGT. The N-terminal domain of the DNA-
protein alkyltransferase family members features a low degree of both 
sequence and length conservation between different species, thus 
precluding an in silico mapping of the residues affected by the nsSNPs 
under study based exclusively upon information currently available in 
the Protein Data Bank (see Fig. S4 in the supplemental material). 
Therefore, to shed light on the molecular basis of the functional defect 
characterizing the MtOGT variants, we determined the crystal structures 
of the wild-type protein and of the MtOGT-R37L mutant at 1.8-Å and 
2.8-Å resolutions, respectively, revealing in both cases one monomer in 
the asymmetric unit. 
An excellent electron density was visible for the entire MtOGT protein 
chain (residues 2 to 165) and allowed the modeling of two molecules of 
glycerol used as the cryoprotectant. Since the crystals of MtOGT-R37L 
were isomorphic with those of MtOGT, we used the model of the wild-
type protein to solve the structure of the mutant. The stereochemistry of 
the refined MtOGT and MtOGT-R37L structures was assessed with the 
program PROCHECK (39), revealing 96% and 98% of residues in the 
preferred region of the Ramachandran plot, respectively (Table 2). 
MtOGT overall structure. Similar to structures of other archaeal (40, 
41) and eubacterial (33) OGTs as well as of human AGT in its ligand-
free (42) and alkylated (43) states or in complex with modified dsDNA 
(25, 44), both MtOGT and MtOGT-R37L fold into a roughly globular 
molecular architecture built up by two domains connected by a long loop 
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and ending in a 10-residue-long tail. In both structures, the tail adopts a 
fully extended conformation, pointing straight outwards from the bulk 
body of the protein (Fig. 3) and contacting the C-terminal domain of the 
adjacent symmetry mate within the crystal lattice (see Fig. S5 in the 
supplemental material). 
The N-terminal domain consists of an antiparallel three-stranded β-sheet 
and connecting loops (residues 2 to 27) sandwiched between a mainly 
randomly coiled region (residues 28 to 46) containing a single helical 
turn at its middle (residues 35 to 39) (h1 in Fig. 3) on one side and a 
structurally conserved -helix on the opposite one (residues 47 to 59) (H2 
in Fig. 3). The C-terminal domain (residues 75 to 155) adopts the 
prototypical all-α-fold and houses the highly conserved functional 
elements that previous biochemical and mutational studies (45, 46) 
demonstrated to be required to perform efficient catalysis. Referring to 
the MtOGT primary sequence, these motifs are (i) the helix-turn-helix 
(HTH) motif, which is responsible for DNA binding at its minor groove 
and bears Arg109, whose structural equivalent in human AGT (i.e., 
Arg128) has been demonstrated to act as a temporary substitute for the 
modified base upon its flipping out from the regular base stacking (25, 
44); (ii) the “Asn hinge” building up one wall of the deep ligand binding 
cavity that accepts the modified base for repairing; (iii) the strictly 
conserved PCHR consensus motif surrounding the catalytic cysteine 
(Cys126); (iv) the active-site loop that participates in the correct 
positioning of the alkylated base inside the ligand binding pocket; and 
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(v) the structurally conserved H6 helix that, by shielding the ligand 
binding cavity on the opposite side of the Asn hinge, contributes 
essential residues for completing both the catalytic triad 
(His127 and Glu153) and the modified-base-bonding network (Lys146) 
(Fig. 3, left) (25, 33, 40–44). 
 
Figure 3 Crystal structure of MtOGT. Shown are cartoon representations of the MtOGT 
structure, as observed from two different points of view. In both images, the N-terminal 
domain, the C-terminal domain, and the connecting loop are colored in green, gray, and 
magenta, respectively. The catalytic cysteine residue (Cys126) is invariably drawn as sticks. 
Functional element labeling and secondary structure element numbering appear in the image 
at the left and at the right, respectively. aa, amino acids. 
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Figure 4 The active-site loop of MtOGT is observed in a solvent-exposed 
conformation. (A) Close-up views of equivalent regions of MtOGT (MTB) (both the 
wild-type protein and the R37L variant are shown at the left), E. coli AdaC (ECO) 
(PDB accession number 1SFE), and human AGT in the absence of ligand (HUM) 
(PDB accession number 1EH6), upon optimal structural superposition of their C- 
terminal domains. In each panel, residues of the region highlighted in the sequence 
alignment (top) and the catalytic cysteine are shown as sticks. The red arrow points 
to the OH group of the structurally equivalent Tyr residue. GOL, glycerol. (B) 
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Cartoon representation of optimally superimposed MtOGT (green), the 
Schizosaccharomyces pombe alkyltransferase-like protein (SpATL) in the absence 
of ligands (yellow) (PDB accession number 3GVA; average RMSD 1.8 Å), and 
SpATL in complex with O6-methylguanine dsDNA (magenta) (PDB accession 
number 3GX4; average RMSD 1.5 Å) (the DNA strands appear as black ribbons). 
(C) Possible mode of binding of alkylated dsDNA to MtOGT (left), resulting upon 
optimal superposition of MtOGT on the structure of a Cys145Ser mutant of human 
AGT (*AGT) in complex withO6-methylguanine (O6-metG) dsDNA (right) (PDB 
accession number 1T38; average RMSD 2.4 Å). Cys126 of MtOGT is observed at 
3.8 Å from the methyl group of the O6-methylguanine. In panels B and C, residues 
discussed in the text appear as sticks, and the water molecule in panel C (W22) is 
rendered as a sphere. 
 
 
The active-site loop of MtOGTs is observed in a solvent-exposed 
conformation. Our crystallographic analysis confirms the high degree 
of structural conservation displayed by the catalytic C-terminal domain 
among members of the protein-DNA alkyltransferase protein family. 
However, different from what was observed in all the crystal structures 
of OGTs, in both the MtOGT and MtOGT-R37L models the active-site 
loop is oriented toward the exterior of the protein body (Fig. 4A), 
adopting a conformation that closely resembles the one displayed by the 
equivalent region in the structures of alkyltransferase-like proteins 
(ATLs) (47) in complex with alkylated DNA (48, 49) (Fig. 4B). 
In principle, such a solvent-exposed conformation of the MtOGT active-
site loop still allows the HTH motif to peculiarly bind the substrate DNA 
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at its minor groove, as disclosed by structural studies of AGT and ATLs 
(25, 44, 48, 49), and is fully compatible with the housing of the modified 
base inside the active site (Fig. 4C, left). In fact, by overlaying our 
structures upon that of an inactive variant of human AGT (catalytic 
Cys145 mutated to Ser) in complex with O6-guanine-methylated dsDNA 
(Fig. 4C, right) (25), we noted that the ligand molecule perfectly fits into 
the MtOGT active site, which appears fully accessible to the flipped-out 
base without requiring any side-chain repositioning. In this 
unprecedented conformation, the hydroxyl group of the highly 
conserved Tyr139 residue is correctly oriented to establish a hydrogen 
bond with the DNA sugar  phosphate backbone at the 5’ side of the 
modified base (Fig. 4C, left), apparently compensating for the absence 
at position 116 of the recognition helix H5 of a residue functionally 
equivalent to Arg135 of human AGT (Gly116 in MtOGT) (Fig. 4C). 
Although in this conformation, Tyr139 is no longer available for 
stacking against the alkylated base on the opposite side with respect to 
the recognition helix H5, the presence in the active site of Arg27 could 
contribute to anchoring the base by contacting its O6 position through a 
water-mediated hydrogen bond (Fig. 4C). 
At present, we cannot univocally discern whether the conformation 
adopted by the active-site loop in our MtOGT structures represents a 
unique, distinctive trait of the mycobacterial proteins or is a consequence 
of crystal packing (see Fig. S5 in the supplemental material); 
nonetheless, the reported data provide further independent support for 
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the proposed conformational plasticity of this region and its central role 
in the control of alkylated-DNA binding (25, 40–44, 48, 49). 
 
Figure 5 Possible structural role of Arg37. (A and B) Close-up views of the 
superposed N-terminal domain and part of the active site of wild-type MtOGT (A) 
and MtOGT-R37L (B), as observed in their respective crystal structures. (C) 
Equivalent regions of a structure-based model of the MtOGT-T15S variant. In all 
images, residues cited in the text appear as sticks, dotted lines indicate close 
interactions (distances appear in angstroms), and water molecules are rendered as 
spheres. 
 
MtOGT structures provide clues to explain the DNA binding 
impairment displayed by MtOGT-R37L. Optimal superposition of the 
available OGT three-dimensional (3D) models from different species 
confirmed the limited structural conservation of their N-terminal domain 
(see Fig. S4 in the supplemental material). In this respect, the MtOGT 
structure allowed us to directly observe the intradomain contacts 
involving the mutated residues under study. In particular, Thr15 and 
Arg37 seem to play a central role in coordinating the network of contacts 
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established between a small number of residues of strands 1 and 2 and 
the region bearing the h1 helix of the facing random coil. In fact, in the 
structure of MtOGT (Fig. 5A), the Thr15 OH group is observed within 
hydrogen- bonding distance of the Arg37 NH2 atom, which is engaged 
in an ion pair with Glu30; in turn, the latter residue coordinates a water 
molecule that is also in hydrogen-bonding contact with the Thr15 OH 
group. The observed hydrogen bond arrangement could provide a likely 
explanation for why the MtOGT-R37L protein displays a more reduced 
affinity toward alkylated DNA than does MtOGT-T15S. Indeed, in the 
structure of the MtOGT-R37L variant (Fig. 5B), the interactions 
involving Arg37 and the chemical identity of the local environment are 
lost, whereas the analysis of a model of the MtOGT-T15S mutant (Fig. 
5C) suggests that these biochemical features remain unaltered, due to the 
presence in Ser15 of a hydroxyl group structurally equivalent to the one 
present in the substituted threonine. 
How might a nonconservative substitution of MtOGT Arg37, which 
maps far away from both the Cys126 reactive center and the currently 
identified DNA binding motifs, produce an impact on protein function, 
as revealed by our in vitro biochemical characterization? In principle, 
there are three possible - and not mutually exclusive - scenarios: the 
R37L mutation could (i) induce conformational changes of the N-
terminal random-coiled region that can affect catalysis, (ii) alter the 
assembly of protein complexes at the damaged site during cooperative 
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DNA binding, and (iii) impair an unexpected participation of the Arg37-
bearing random coil to direct DNA binding (Fig. 6). 
For the first scenario, it must be noted that by comparing the structures 
of wild-type MtOGT and the MtOGT-R37L variant (Fig. 5), we did not 
observe any dramatic conformational change affecting the protein 
backbone (average root mean square deviation [RMSD] 0.3 Å). 
Moreover, even taking into account the more limited resolution of the 
MtOGT-R37L model, the only appreciable differences at the level of the 
N-terminal domain are represented by Glu30 and Arg27, whose side 
chains appear largely undefined in the structure of the mutated protein 
(Fig. 5B). Similarly, the low increase of the thermal factor values of the 
N-terminal random-coil residues is comparable for both the MtOGT and 
MtOGT-R37L models (not shown). Thus, our data do not indicate an 
increased conformational flexibility of this region in the mutated protein, 
possibly directly interfering with the catalysis. 
Regarding the second scenario, seminal studies on human AGT revealed 
a participation of discrete regions of the N-terminal domain in the 
cooperative behavior displayed by the protein during DNA recognition 
(10, 23, 24), and our biochemical characterization shows a severe 
undermining of MtOGT DNA binding activity upon R37L mutation 
(Table 1 and Fig. 2); these observations prompted us to speculate that 
the lack of Arg37 might alter the possibility of establishing optimal 
protein-protein contacts required for a tight assembly of OGT monomers 
at the alkylated site.  
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Figure 6 Schematic representation of the possible functional consequences of the 
replacement of Arg37 with Leu in MtOGT. (i) Direct interference in the dealkylation 
reaction; (ii) reduced capability of establishing protein-protein interactions and tight 
monomer packing during cooperative DNA binding; (iii) direct participation of 
Arg37 in DNA binding. The N-terminal domain, the domain-connecting loop, and 
the C-terminal domain of the wild-type protein are colored green, magenta, and 
white, respectively. The MtOGT-R37L structure is uniformly rendered in red; the 
modeled dsDNA appears in yellow. 
 
Consequently, although we did not observe any significant structural 
difference between the wild-type and mutated MtOGT, we cannot rule 
out that a repositioning of the N-terminal random coil could become 
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evident only in the presence of DNA, therefore affecting the 
cooperativity of DNA binding. The third hypothesis mentioned above, 
implying a direct involvement of the Arg37-bearing protein moiety in 
DNA binding, is strongly suggested by the results of our biochemical 
analysis but needs further site-directed mutagenesis analysis and 
structural investigations to be definitively assessed. Overall, our results, 
besides revealing a high level of structural conservation among DNA-
protein alkyltransferases, could provide a framework to orient future 
studies aimed at an understanding of the molecular mechanism leading 
to the observed functional defect shown by the analyzed MtOGT 
variants. In conclusion, we showed that while the catalytic activity of the 
mutated MtOGT variants toward the synthetic substrate used is not 
diminished relative to the wild-type protein, the same mutations result in 
decreased affinity toward the physiological alkylated-DNA substrate. 
Consequently, the mutants under analysis are less efficient than the wild-
type protein in carrying out the complete catalytic cycle required for 
alkylated-DNA direct repair in vitro. However, due to the critical 
contribution of the physiological context in determining whether or not 
a specific mutation in a protein impacts its function, definitive proof of 
a role of these MtOGT nsSNPs in altering alkylation damage sensitivity 
and mutation frequency of the corresponding M. tuberculosis strain will 
come only from future in vivo studies.     
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SUPPLEMENTAL METHODS  
 
Expression and purification of wild-type MtOGT and point mutants 
The three recombinant proteins MtOGT, MtOGT-T15S and MtOGT-
R37L were purified by FPLC (Akta Basic Instrument GE Healthcare) 
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from 1 L of the corresponding auto-induced bacterial culture adopting 
the following workflow. 50 mL of clarified lysate in buffer A [Tris-HCl 
20mM pH 7.8 and a commercial protease inhibitor cocktail (Sigma)] 
were loaded onto a HiTrapQ pre-packed anion exchange column. The 
retained proteins were then eluted using a linear 0-0.5 M NaCl gradient. 
Recombinant protein-containing fractions were dialysed against buffer 
A, applied onto a MonoQ pre-packed column (GE Healthcare) and 
protein elution was obtained as above. 
Recombinant protein-containing fractions from the last anion-exchange 
chromatography step were pooled, desalted by dialysis against buffer A 
and loaded onto a HiTrap Heparin disposable column (GE Healthcare). 
Protein elution was obtained by a linear 0-1.0 M NaCl gradient and the 
eluted fractions containing the recombinant protein were pooled, 
concentrated to 1 mg/mL by using 10 kDa NMWCO ultrafiltration 
device (Vivaspin, Vivascience) and loaded onto a Superdex 200 10/300 
size exclusion chromatography column (GE Healthcare) using buffer B 
[20 mM Tris-HCl pH 7.8, 150 mM NaCl] as the mobile phase. Fractions 
corresponding to the main peak were concentrated to 5 mg/mL by using 
a 10 kDa NMWCO Vivaspin device. During the entire procedure the 
recombinant protein was monitored by standard SDS⁄PAGE analyses 
(example given in Supplementary Figure 1) and protein concentration 
was determined by the Bradford assay (Sigma). If not immediately used, 
the purified proteins were stored in aliquots at -80 °C. 
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Table S1  Oligonucleotides used in the present work  
 
MtOGTfwd(a) 5’-ATATCCATGGTTCACTACCGCACCATCGATAGC-3’ (Nco I) 
MtOGTrev(a) 5’-AAAGGATCCTCAGTCGAAGAGCGTCAAGTCTG-3’ (Bam HI) 
  
T15S fwd(b)  5’-CCCATCGGGCCATTA AGC CTGGCCGGGCATGGC-3’  ACC 
T15S rev  5’-GCCATGCCCGGCCAGGCTTAATGGCCCGATGGG-3’ 
  
R37L fwd(c)  5’-CGTATGAGCCAAGC CTC ACACACTGGACACCC-3 CGC 
R37L rev  5’-GGGTGTCCAGTGTGTGAGGCTTGGCTCATACG-3’ 
  
UPmet (d)  5’-GGACACTGTACGTTAAGGCG*ATCGAATTAGGATTAA-3’ 
DOWN  5’-GGTTAATCCTAATTCGATCGCCTTAACGTACAGTGT-3’ 
  
A+ oligo(e)  5’-TMR-GCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTA-3’ 
D- oligo  5’-TAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGC-3’ 
 
(a) Restriction sites for the endonucleases indicated in brackets are underlined; (b) (c) 
point-mutation in each oligonucleotide appears in bold; (d) the methylguanine residue 
in the UPmet oligonucleotide is labeled by an asterisk; the ds-DNAmet probe used in 
enzyme kinetics analysis has been prepared by annealing UPmet and DOWN 
oligonucleotides (e) “TMR” indicates the TAMRATM fluorescent group;  the dsDNA 
probe used in EMSA analysis has been prepared by annealing A+ and D- 
oligonucleotides. 
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Fig. S1 
 
 
 
Purification of MtOGT, MtOGT-T15S and MtOGT-R37L. 4 μL of each purified 
protein (5 mg/mL) were separated using a 15% acrylamide-bisacrylamide gel in 
SDS-PAGE and visualized by Coomassie brilliant blue staining. The three proteins, 
independently loaded onto a Superdex 200 10/300 size exclusion chromatography 
column (GE Healthcare), invariably eluted at Ve=17.2 mL, which corresponds to a 
MW of 18 kDa, as calculated on the basis of the calibration curve of the column.  
SEC eluted volume :             17.2 mL 
100 
45 
20 
12 
8 
MWM 
(kDa) 
60 
30 
T15S R37L WT 
Expected MW = 17.8 kDa 
Purified protein 
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Fig. S2 
 
 
 
Example of the determination of the kinetic constants of the reaction catalyzed by 
the recombinant proteins under study. A. Scheme of the assay with the fluorescent 
substrate/inhibitor SNAP-Vista GreenTM (VG); B. Time-course experiments of 
covalent modification of 5 μM MtOGT incubated with VG in the range of 0.1-10 μM 
(VG concentration appears at the right of each corresponding curve) and taking 
aliquots at 0, 2, 5, 10, 30, 60 min. Similar sets of measurements were carried out for 
both the MtOGT-T15S and MtOGT-R37L mutated proteins (not shown); C. Plot of 
the first-order rate constants for covalent modification of MtOGT (kobs) as a function 
of SNAP-Vista Green™ (VG) concentration. Rate values obtained in the time course 
experiments were fitted according to equation 1 (see the “Materials and Methods” 
section of the main text). 
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Fig. S3 
 
 
 
Determination of the DNA dissociation constants of the reaction catalyzed by 
MtOGT, MtOGT-T15S and MtOGT-R37L.  Plots of the variation of KVG of 
MtOGT (A), MtOGT-T15S (B) and MtOGT-R37L (C) as a function of the dsDNAmet 
concentration. Data were fitted according to equation 2 (see the “Materials and 
Methods” section of the main text) that allowed the calculation of the dissociation 
constant of each enzyme for the dsDNAmet ligand (KDNA), indicated by a red arrow 
in each panel. 
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Fig. S4 
 
 
 
 
Structural comparison of MtOGT with OGTs from different species. A. The figure 
shows the primary ClustalW-generated sequence alignment of equivalent moieties 
of the N-terminal domains of OGTs whose structures have been deposited with the 
protein data bank. MTB: Mycobacterium tuberculosis; SULFO: Sulfolobus 
tokodaii; ECOLI: Escherichia coli; PYRO: Pyrococcus kodakaraensis; METJ: 
Methanococcus jannaschii; HUM: human AGT. The random-coiled region in M. 
tuberculosis OGT is highlighted in green and residues belonging to the h1 helical 
turn are boxed. The red arrowheads label the residues mutated in MtOGT-T15S and 
MtOGT-R37L, respectively. Residues rendered in red in the human sequence are not 
visible in the human AGT structures. B. Cartoons of the indicated structures after 
optimal superposition to the MtOGT model; each panel shows only the N-terminal 
domain (depicted in green in MtOGT and in black in all other structures) and part of 
the inter-domain connecting loop (invariably colored in magenta). 
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Fig. S5 
 
 
Crystal packing of MtOGT. Close up view of the interacting regions of the C-
terminal domain of one chain (gray) and the tail of its symmetry mate (yellow, 
residues labeled by an asterisk) as observed in the MtOGT crystal lattice (upper 
image); only the residues involved in the closest interactions are labeled and shown 
as sticks; bond distances (Å) are indicated as dotted lines. 
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Summary 
 
In Mycobacterium tuberculosis the O6-methylguanine methyltransferase 
protein (OGT/AdaB) plays a main role in protecting the bacterial GC-
rich genome from the pro-mutagenic potential of O6-methylated 
guanine. Interestingly, several multi-drug resistant M. tuberculosis 
strains show nonsynonymous single-nucleotide polymorphisms (nsSNP) 
in their OGT-encoding sequence (T15S and R37L).  Although the 
functional consequences of such point-mutated OGT variants on the 
biology of the corresponding M. tuberculosis strains remain 
undetermined, we recently demonstrated in vitro that the recombinant 
mutated proteins (i.e. MtOGT-T15S and MtOGT-R37L) display an 
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impaired activity, with MtOGT-R37L showing a 10-fold lower affinity 
for double stranded DNA containing O6-methylguanine with respect to 
the wild-type protein. Our concomitant structural investigations 
provided us with possible scenarios explaining the molecular bases of 
such a catalytic defect, and added elements of novelty to currently 
available structural description of this class of protein, namely the 
conformation adopted in MtOGT by the active site loop.  
We describe here the biochemical characterization of two structure-
based designed point-mutated variants of MtOGT (i.e. MtOGT-R37K 
and MtOGT-R37E) aimed at better understanding the functional role of 
Arginine 37 during the catalysis. Similar analyses on the MtOGT-Y139F 
- a MtOGT version mutated at the level of a highly conserved tyrosine 
of the protein active site loop-, confirms the fundamental role of this 
residue in catalysis, although disclosing an unprecedented mode of 
action.  
 
Introduction  
 
Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis 
(TB), displays a remarkable genetic stability (1) despite the continuous 
exposure to pro-mutagenic and genotoxic stresses that could 
compromise both the persistence in the host as well as the reactivation 
of the bacillus from the dormant state (2). In particular, during its long-
term stay inside the infected macrophages, MTB must deal with potent 
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endogenous DNA-alkylating chemical species originating by the action 
of highly reactive oxidative and nitrosative radicals (3). Similarly to 
what observed in other organisms, M. tuberculosis attains alkylated-base 
repair either using multi-enzymatic systems or by directly removing the 
alkyl adduct from the modified base by sacrificing a molecule of a DNA-
protein alkyltransferase (4, 5). O6-methylguanine methyltransferase 
(OGT) (E.C. 2.1.1.63) acts through a suicidal mechanism (6) by 
performing the irreversible transfer of the O6-alkyl group from the 
modified guanine to a strictly conserved cysteine residue buried in its 
active site, which is hosted in the C-terminal domain of the protein. 
Ground-breaking X-rays crystallography studies on the human ortholog 
O6-alkylguanine DNA alkyltransferase (AGT) (6, 7) in complex with 
double stranded olignucleotides, containing either the physiological 
substrate O6-methylguanine or substrate analogues (8, 9), revealed the 
molecular details of the protein association with the alkylated double 
stranded DNA (dsDNA). These results showed that human AGT - as 
well as alkyl-transferase like proteins (10) - binds the substrate DNA 
through a novel mechanism, by establishing contacts between a 
canonical helix-turn-helix motif in the C-terminal domain of the protein 
and the DNA minor groove. The alkylated guanine residue appears 
flipped out from the regular base stacking and housed into the active site 
pocket, thus resulting correctly positioned with respect to the catalytic 
cysteine (7, 8, 9). The protein-substrate complex is further stabilized by 
residues of the active site loop, a crucial structural element of the C-
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terminal domain that has been invariably observed in a “pointing 
inwards” conformation in all other ligand-free or DNA-bound OGT 
crystal structures. 
As in most bacterial species, mycobacterial ogt gene (adaB; Rv1316c) is 
part of an adaptive response operon that has been recently fully 
functionally characterized, confirming its role in protecting 
mycobacterial genome against the pro-mutagenic potential of DNA 
alkylation (11). Several lines of experimental evidences support this 
observation: i) the OGT gene expression profile changes during infection 
and in response to pro-alkylating compounds (11, 12, 13); ii) the hyper-
mutator phenotype displayed by a MNNG (N-methyl-N’-nitro-N-
nitrosoguanidine)-treated MTB strain lacking the ogt operon could be 
rescued by gene trans-complementation (14); and iii) the trans-specific 
knock-in of an Ada/OGT-defective Escherichia coli strain with the M. 
tuberculosis ogt gene alone, suppresses its alkylation damage sensitivity 
and restores mutation frequencies to wild-type levels  (11). Notably, a 
number of geographically widely distributed MTB W-Beijing strains 
and multi-drug resistant isolates show nonsynonymous SNPs in their 
OGT-encoding sequence, resulting in amino acid substitutions at the 
poorly functionally characterized N-terminal domain of the enzyme (15, 
16, 17).  
In order to reveal a possible direct impact of these mutations (i.e. 
threonine 15 and arginine 37 replaced by serine and leucine, 
respectively) on MtOGT protein function, we recently performed the 
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biochemical and structural characterization of the MtOGT-T15S and 
MtOGT-R37L recombinant proteins that mimic the ones occurring in 
clinical isolates (18). Interestingly, the MtOGT-R37L mutant displays a 
severely impaired catalytic activity as a consequence of its ten-fold lower 
affinity for methylated double-stranded DNA with respect to the wild-
type protein. The high-resolution crystal structures of both MtOGT and 
MtOGT-R37L provided clues to understand the molecular bases of the 
observed catalytic defect showed by the MtOGT-R37L variant, that was 
suggested to be possibly due to an unexpected participation of Arg37 to 
direct DNA binding and/or to its role in the cooperative protein assembly 
at the alkylated-DNA site during substrate recognition. Our analysis also 
revealed that, notwithstanding the high degree of overall structural 
conservation at the level of the catalytic C-terminal domain of members 
of the alkyltransferase protein family, in both the wild-type and mutated 
MtOGT crystal structures the active site loop invariantly adopts a 
“pointing outwards” conformation, thus exposing a highly conserved 
tyrosine residue (Y139 in MtOGT) to the bulk solvent (18).  
By adopting an experimental approach that combines biochemical and 
X-rays crystallography studies, in the present work we carried out the 
determination of the enzyme kinetics and the structural characterization 
of a new panel of recombinant MtOGT point-mutated variants that were 
specifically designed to further confirm our previous conclusions and 
clarify the issues left unanswered. In particular, our current results 
underline the requirement of a positive charged residue at position 37 of 
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the N-terminal domain of the protein, corroborating the hypothesis that 
sees Arg37 directly involved in protein assembling and/or direct DNA 
binding during catalysis.  Moreover, the crystal structure of MtOGT-
Y139F confirms the peculiar conformation of the active site loop in 
MtOGT and allow us to propose a specific role for Y139 in MtOGT-
performed alkylated-DNA repair.  
 
 
Materials and methods 
 
Chemicals. All reagents were obtained from Sigma-Aldrich unless 
otherwise specified. 
 
Construction of pET-MtOGT-R37K, pET-MtOGT-R37E and pET-
MtOGT-Y139F expression vectors - The pET-MtOGT construct 
coding for the wild-type M. tuberculosis O6-methylguanine 
methyltransferase (orf: Rv1316c) (19) was invariably used as the DNA 
template in PCR-based site-directed mutagenesis experiments, using the 
QuikChange II site-directed mutagenesis kit reagents (Stratagene) and 
the three primer pairs R37Kfwd/R37Krev, R37Efwd/R37Erev and 
Y139Ffwd/Y139rev (Table 1). The region encoding the corresponding 
point-mutated OGT variant in each resulting expression construct 
(namely pET-MtOGT-R37K, pET-MtOGT-R37E and pET-MtOGT-
Y139F) was verified by sequencing (Eurofins MWG Operon). 
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Table 1- Oligonucleotides used in the present work. 
R37K fwd(a)  5’- GACGTATGAGCCAAGCAAGACACACTGGACACCCGACC -3’   
R37K rev  5’- GGTCGGGTGTCCAGTGTGTCTTGCTTGGCTCATACGTC -3’ 
  
R37E fwd(a)  5’- GACGTATGAGCCAAGCGAGACACACTGGACACCCGACC-3  
R37E rev  5’- GGTCGGGTGTCCAGTGTGTCTCGCTTGGCTCATACGTC-3’ 
  
Y139F fwd(a)  5’- CGGAAAGCTCACCGGGTTCGGCGGTGGAATCAAC-3’  
Y139Frev  5’- GGTTGATTCCACCGCCGAACCCGGTGAGCTTTCCG-3’ 
  
UPmet (b)  5’- GGACACTGTACGTTAAGGCG*ATCGAATTAGGATTAA-3’ 
DOWN  5’- GGTTAATCCTAATTCGATCGCCTTAACGTACAGTGT-3’ 
  
A+ oligo(c)  5’-TMR-GCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTA-3’ 
D- oligo  5’-TAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGC-3’ 
(a) point-mutation in the “sense” oligonucleotide appears in bold; (b) the methylguanine residue is 
labeled by an asterisk; (c) “TMR” indicates the TAMRATM fluorescent group.   
 
Expression and purification of point-mutated MtOGT variants - 
The procedure adopted to express and purify the MtOGT-R37K, 
MtOGT-R37E and MtOGT-Y139F point-mutated versions of MtOGT 
used in biochemical and structural analyses was previously reported 
(18).  
 
Activity assays and enzyme kinetics analysis - To measure the 
alkyltransferase activity of wild-type MtOGT and its point-mutated 
variants MtOGT-R37K, MtOGT-R37E and MtOGT-Y139F, a 
fluorescence assay using SNAP-Vista Green reagent (New England 
BioLabs) (here referred to as VG for brevity) was used, as previously 
described (20). Protein bands from SDS-PAGE were visualized by direct 
gel imaging (VersaDoc 4000; Bio-Rad), and their fluorescence 
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intensities (FIs), corresponding to the reacted protein, were corrected for 
the actual amount of protein loaded into each lane by measuring the 
intensity of bands after Coomassie brilliant blue R250 staining. Activity 
assays at different pH values were performed with 1× Fluo reaction 
buffer containing 50.0mM different buffering species, allowing the 
determination of the pH optimum of the reaction used in all subsequent 
experiments (data not shown). Assuming a 1:1 substrate-enzyme 
stoichiometry and irreversible binding, incubation of a fixed amount of 
protein (5.0 μM) with VG (in the range of 0.1 to 20.0 μM) for 1 h at 25°C 
gave corrected FI data, which were fitted by a linear equation whose 
slope gave a direct reference value of FI/μM protein, which was then 
used to estimate the amount of covalently modified protein (expressed 
in picomoles) in time course experiments. The latter assays were 
performed at 25°C using different protein/VG molar ratios and taking 10 
μl aliquots at different time intervals. Plots of the picomoles of reacted 
protein versus time were fitted by exponential equations to determine the 
apparent rates for covalent modification (kobs). These values were plotted 
versus the VG doses ([VG]) by using the following hyperbolic equation: 
 
                           𝑘obs   =
𝑘
1+KVG /[VG]
                                         (1) 
 
where k and KVG are the rate of covalent linkage and the dissociation 
constant for the free enzyme and free VG reagent during the first 
collision step (before covalent modification), respectively. In order to 
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calculate the apparent KVG values (KVG
app) of proteins for VG as a 
function of the double-stranded methylated DNA (dsDNAmet) 
concentration, time course experiments such as those described above 
were performed in the presence of increasing fixed doses of dsDNAmet. 
Data were fitted according to the following linear equation: 
 
                             KVG
      app
=
KVG 
KDNA
 [dsDNAmet]+ KVG                       (2) 
 
where KDNA is the dissociation constant of the protein for the dsDNA
met 
substrate. The results of these enzyme kinetics analyses are summarized 
in Table 2. 
 
Electrophoretic mobility shift assay (EMSA) - A 40-bp 6-
carboxytetramethylrhodamine (TAMRA)-labeled double-stranded DNA 
probe (0.1 µM) was incubated at 25°C for 10 min with different amounts 
of proteins in the range of 0.0 to 120.0 µM in a total volume of 10.0 µl 
in 1× binding buffer (20.0 mM Tris-HCl [pH 7.5], 50.0 mM KCl, 0.1 
mM dithiothreitol [DTT], and 10% glycerol). Samples were loaded onto 
an 8% polyacrylamide-bisacrylamide native gel in 1× Tris-borate-EDTA 
(TBE). Signals were visualized by direct gel imaging using a green light-
emitting diode (LED)/605-nm-band-pass filter as excitation/emission 
parameters, respectively. 
 
  Chapter 4 
98 
 
Crystallization - Crystals of either MtOGT-R37K or MtOGT-Y139F 
were grown by the hanging drop vapor diffusion method mixing 2 µl of 
the corresponding protein solution at 5 mg/ml with an equal volume of a 
reservoir solution containing 0.1 M HEPES (pH 7.5), 4% (wt/vol) 
polyethylene glycol 8000 (PEG 8000), and 4% (wt/vol) ethylene glycol 
for MtOGT-R37K or 0.1 M HEPES (pH 7.5), 4% (wt/vol) polyethylene 
glycol 8000 (PEG 8000), and 8% (wt/vol) ethylene glycol for MtOGT-
Y139F. The drop was equilibrated against 800 µl of the reservoir 
solution at 4°. Crystals used in X-ray diffraction experiments grew to 
maximum dimensions of 0.2 mm in about 2 weeks.  
 
Structure determination - For X-ray data collection, crystals of both 
MtOGT-R37K and MtOGT-Y139F were taken directly from the 
crystallization droplet, rapidly equilibrated in a solution containing the 
crystallization buffer and 15% glycerol as a cryoprotectant, and flash-
frozen at 100 K under liquid nitrogen. A complete data set of the 
MtOGT-R37K crystal was collected at 100 K to a 2.3-Å resolution using 
synchrotron radiation (λ= 0.979 Å) at the ID14-EH4 beam line 
(European Synchrotron Radiation Facility [ESRF], Grenoble, France), 
equipped with an ADSC detector. Analysis of the collected diffraction 
data set allowed us to assign the crystal to the orthorhombic space group 
P21212, with the cell dimensions a = 59.10  Å, b = 81.88 Å, and c = 38.27 
Å, containing one molecule per asymmetric unit, with a corresponding 
solvent content of 52%. For all data collections, diffraction intensities 
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were evaluated, integrated, and scaled by using the CCP4 suite of 
programs (21). The structure of MtOGT-R37K was solved by molecular 
replacement using the program Phaser (22) and the structure of M. 
tuberculosis O6-methylguanine-DNA methyltransferase as the search 
model (18) (Protein Data Bank [PDB] accession number 4BHB) 
omitting water/ligand molecules and Arg37 side-chain. The resulting 
electron density map was of high quality and allowed automatic tracing 
by the program ARP/wARP (23), which was also used for adding solvent 
molecules. The program Coot (24) was used for manual rebuilding, and 
the program PHENIX (25) was used for crystallographic refinement. 
A complete data set of the MtOGT-Y139F crystal was collected at 100 
K to a 2.6-Å resolution using synchrotron radiation (λ= 0.99 Å) at the 
ESRF ID14-EH4 beam line equipped with an ADSC detector.  
The structure of MtOGT-Y139F was solved by molecular replacement 
using the program Phaser (22) and the structure of M. tuberculosis O6-
methylguanine-DNA methyltransferase as the search model (Protein 
Data Bank [PDB] accession number 4BHB) (in which water/ligand 
molecules and Tyr139 side-chain atoms were omitted). 
Model building and crystallographic refinement were performed 
following the same procedure described above for MtOGT-R37K. Data 
collection, phasing, and refinement statistics are given in Table 2. 
Structural superpositions were performed with the Superpose program 
of the CCP4 suite (21). Figures illustrating the structural analysis were 
generated with PyMol (26). 
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Results and Discussion 
 
Expression and purification of MtOGT-R37K, MtOGT-R37E and 
MtOGT-Y139F - As described in the “Introduction” section, previous 
results from the in vitro characterization of MtOGT and its mutated 
variants mimicking the ones occurring in clinically relevant MTB strains 
(18) highlighted the requirement of the R37 residue for optimal catalysis. 
This result was quite unexpected, since R37 belongs to the OGT N-
terminal domain that has never been reported to assist the removal of the 
alkyl group from the modified base or to directly participate in DNA 
binding. The second element of novelty disclosed from those studies 
consisted in the observation of the solvent-exposed conformation 
adopted by the Y139 residue of the active site loop that has never been 
observed before in the crystal structure of ligand free or DNA-bound 
OGTs of other species (8, 9, 27, 28, 29).  
Therefore, to specifically investigate the molecular role of R37 and Y139 
in MtOGT, we constructed the pET-MtOGT-R37K, the pET-MtOGT-
R37E and pET-MtOGT-Y139F expression plasmids, which drive the 
synthesis in E. coli of the three (untagged) OGT variants that could be 
reproducibly purified at high yield by FPLC-based standard techniques. 
We obtain pure and highly homogeneous preparations of the three 
mutated proteins that, as already demonstrated for the wild-type MtOGT 
(18), behave as monomers in solution (Figure 1); this observation 
confirms that the substitution of R37 by a lysine or a glutamate residue 
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(in MtOGT-R37K and MtOGT-R37E, respectively) and the replacement 
of Y139 by a phenylalanine (in MtOGT-Y139F) do not affect the overall 
stability of the corresponding mutated protein and do not alter its 
quaternary structure in the absence of ligands. 
 
Figure 1  
  
  
 
 
 
 
 
 
 
 
Purification of MtOGT-R37K, MtOGT-R37E and MtOGT-Y139F. 5 μL of each 
purified protein (5 mg/mL) were separated using a 15% acrylamide-bisacrylamide 
gel in SDS-PAGE and visualized by Coomassie brilliant blue staining. The three 
proteins, independently loaded onto a Superdex 200 10/300 size exclusion 
chromatography column (GE Healthcare), invariably eluted at elution volume of 
17.2 mL, which corresponds to a MW of 18 kDa, as calculated on the basis of the 
calibration curve of the column. 
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Enyme kinetics study of MtOGT-R37K, MtOGT-R37E, and 
MtOGT-Y139F.  
 
By adopting a biochemical assay based on the SNAP-VISTA Green™ 
molecule (VG), a fluorescent derivative of O6-benzylguanine (18, 20), 
we determined the kinetic constants for the covalent modification of the 
three point-mutated variants of MtOGT in the presence of increasing 
amounts of a double-stranded DNA fragment containing an internal O6-
methylated guanine (dsDNAmet), which represents the physiologic 
substrate of  OGT and consequently competes with the VG reagent 
during the trans-alkylation reaction (i.e. from the modified base to the 
catalytic cysteine of the enzyme, Figure 2). According to equation 2 in 
the “Material and Methods” section, a linear plot of the KVG values as a 
function of the dsDNAmet concentration allowed the calculation of the 
dissociation constant (KDNA) of MtOGT-R37K, MtOGT-R37E and 
MtOGT-Y139F for dsDNAmet (Table 2).  
Our data show that the MtOGT-R37E point mutant exhibits a five-fold 
lower affinity for dsDNAmet (KDNA= 1.14 ± 0.15 µM) with respect to 
MtOGT (KDNA= 0.24 ± 0.11 µM), while the replacement of Arg37 by a 
lysine residue does not produce such a significant effect; indeed the 
dsDNAmet binding affinity of MtOGT-R37K is in the range of the one 
displayed by the wild-type protein (KDNA= 0.38 ± 0.2 µM).  
These kinetics data corroborate our working hypothesis that the 
functional role of Arg37 could be to providing a positively charged  
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Figure 2 
Fluorescence-based assay used for the characterization of MtOGT enzyme 
kinetics. (A) Scheme of the transalkylation reaction of MtOGT with the fluorescent 
substrate/inhibitor SNAP-VISTA GreenTM (VG); (B) SDS-PAGE analysis of 
increasing amount of  MtOGT covalently bound to the VG. (C) SDS-PAGE analysis 
of MtOGT incubated in the presence of both VG and dsDNAmet that competes with 
VG for alkyltransferase reaction.  
 
group at this specific position of the MtOGT N-terminal domain, that 
would be required for establishing optimal protein-protein and/or 
protein-DNA contacts during substrate recognition. 
Considering the MtOGT-Y139F mutant, its ten-fold lower affinity for 
dsDNAmet (KDNA= 2.19 ± 0.5 µM)
 than the wild type enzyme confirms 
the crucial role of Tyr139 of the active site loop in MtOGT-mediated 
H
+
 
MtOGT fluorescence after 
VG-reaction 
MtOGT fluorescence after 
VG-reaction in presence of 
competing dsDNA
met
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repairing of methylated guanine in dsDNA, as already fully established 
for the equivalent residue in other OGTs. (30, 31, 32, 33). 
 
Table 2- Kinetic constants of the reaction catalysed by MtOGT (18) and 
corresponding mutants.  
 
 
 
 
 
 ds-DNA
met
 
(µM) 
Mean k (s
-1
) ± 
SD 
Mean K
VG 
(µM) ± SD 
Mean KDNA
  
(µM) ± SD 
     
 0 0.12 ± 0.02 1.82 ± 0.4  
 0.63 0.14 ± 0.02 3.53 ± 0.5  
MtOGT 1 0.10 ± 0.02 5.29 ± 0.9 0.24 ± 0.11 
 1.25 0.14 ± 0.02 8.68 ± 0.8  
     
 0 0.07 ± 0.01 0.42 ± 0.1  
 0.63 0.07 ± 0.01 0.88 ± 0.2  
MtOGT-R37K 1 0.07 ± 0.01 0.96 ± 0.5 0.38 ± 0.2 
 1.25 0.06 ± 0.01 1.43 ± 0.5  
     
 0 0.03 ± 0.01 1.72 ± 0.4  
 0.63 0.04 ± 0.01 2.81 ± 0.6  
MtOGT-R37E 1 0.05 ± 0.01 3.47 ± 0.2 1.14 ± 0.15 
 1.25 0.04 ± 0.02 3.61 ± 0.4  
     
 0 0.02 ± 0.02 0.69 ± 0.3  
 0.63 0.03 ± 0.02 0.73 ± 0.4  
MtOGT-Y139F 1 0.02 ± 0.01 0.93 ± 0.4 2.19 ± 0.5 
 1.25 0.02 ± 0.02 1.05 ± 0.5  
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Figure 3   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Band shift analysis of MtOGT (wild type) (18), MtOGT-R37K, MtOGT-R37E and 
MtOGT-Y139F proteins. Lane 1, 1 pmol of fluorescent double-stranded DNA probe 
(DNA); lanes 2 to 9, increasing amounts of protein (P) incubated in the presence of 
the probe at the indicated DNA/protein molar ratio. 
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Direct DNA binding analysis of MtOGT-R37K, MtOGT-R37E, and 
MtOGT-Y139F.  
 
The enzyme kinetics characterization reported in the previous section 
shows that a non-conservative substitution of Arg37 - as observed in the 
recombinant MtOGT-R37L protein mimicking the one characterizing a 
number of frequently isolated MTB strains as well as in the MtOGT-
R37E variant described in the present study- results in a catalytically 
inactive MtOGT (Table 2) (18). To understand whether this defect could 
be attributable to a reduced capability of the protein to bind the substrate, 
we performed an EMSA-based analysis (Figure 3). Interestingly, the 
MtOGT-R37E mutant showed a significant reduction in dsDNA band 
shift activity, with a plateau at a DNA/protein molar ratio of 1:600 
(Figure 3C), whereas the wild type MtOGT and the MtOGT-R37K 
variant induce a complete shift at a DNA/protein molar ratio of 1:150 
(Figure 3, panels A and B respectively). Taken together our data indicate 
that the presence of a positively charged group at position 37 of the N-
terminal domain of MtOGT is required for efficiently recognizing and 
binding dsDNA. Since an arginine residue at this position does not 
appear as a conservative trait in OGTs, it emerges as a peculiar feature 
of the mycobacterial enzyme.  
An equivalent analysis using the MtOGT-Y139F protein reveals that this 
point-mutated variant does not show any impairment in unmodified 
dsDNA cooperative binding (Figure 3D); indeed, MtOGT-Y139F 
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behaves as the wild-type enzyme in EMSA-based experiment, reaching 
a plateau in band shift activity at a DNA/protein molar ratio of 1:150. 
Notably the MtOGT-Y139F DNA binding defect is detectable only in 
presence of a dsDNAmet (see Table 2), suggesting an involvement of 
Tyr139 in specifically stabilizing the modified base upon DNA binding. 
 
MtOGT-R37K structure analysis 
 
Previous X-ray crystallography-based structural investigations on MTB 
OGT (18), allowed us to speculate about the possible mechanism/s by 
which the Arg37 residue -mapping at the poorly structurally conserved 
and functionally characterized N-terminal domain of the protein- could 
take part in the de-alkylation reaction and/or in mediating protein 
recruiting at the alkylated-site on DNA, two mandatory steps along 
catalysis previously attributed solely to elements/motifs of the C-
terminal domain of the protein. We postulated that the non-conservative 
substitution of MtOGT Arg37 by leucine -as observed in the OGT-R37L 
mutant- could affect protein function either by altering the local 
conformation of the N-terminal domain, or by interfering with the 
assembling of protein complexes at the site of damage or by impeding a 
direct participation of Arg37 to direct DNA binding. 
To discriminate between these hypotheses, we expanded our 
comparative structural analysis of MTB OGT to include the 2.3-Å 
crystal structure of MtOGT-R37K (Table 3) and a model of the MtOGT-
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R37E, since in this latter case we did not obtain single crystals suitable 
for X-ray diffraction experiments. 
Figure 4A shows that in wild type MtOGT Arg37 is involved in a 
hydrogen bonding network established between residues of strand β1 
and of the facing random coil. As already reported, the amino acid 
substitution of Arg37 by leucine (MtOGT-R37L, Figure 4B) indeed 
destroys this network of contacts, with no evident effects on the local 
fold of the protein. Notably, in both the MtOGT-R37K crystal structure 
(Figure 4C) and the structure-based model of the MtOGT-R37E mutant 
(Figure 4D) the hydrogen bonding network present in the wild-type 
enzyme appears fully rebuilt; however, our biochemical studies using the 
VG-based assay (Table 2) reveal that these two latter MtOGT variants 
profoundly differ in their ability of sustaining catalysis, with MtOGT-
R37E displaying a five-fold lower affinity for dsDNAmet with respect to 
MtOGT-R37K. 
Therefore, we conclude that the role of Arg37 in MtOGT is to provide a 
positive charge at that specific position, and not to simply stabilize the 
overall fold of the N-terminal domain by coordinating the local bonding 
scheme. We still need to assess whether this positive charged residue is 
directly involved in DNA binding or if it mediates protein-protein 
interactions. To this end we performed co-crystallization experiments 
using the wild type protein and a modified double stranded DNA 
oligonuclotide, which can be covalently bound by the protein. These 
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trials yielded single crystals diffracting at low resolution, and the 
optimization of crystallization conditions have been undertaken.  
 
 
 
 
Close-up views of the N-terminal domain of MtOGT and mutated variants. (A) 
wild-type MtOGT (pdb: 4BHB); (B) MtOGT-R37L (pdb: 4BHC); (C) MtOGT-
R37K (present work) upon optimal superposition of the corresponding crystal 
structures. (D) structure-based model of the MtOGT-R37E variant. 
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Table 3- Data collection, phasing and refinement statistics. 
 
 MtOGT-R37K  MtOGT-Y139F 
Data collection  
Space Group  
    
P21212  P21212  
Wavelength (Å)  0.979  0.99  
Resolution (Å)  2.3  2.6  
Total reflections  50946  17965  
Unique reflections  8668  5706  
Mean(I)/sd(I)  26.7 (8.5)  10.8 (2.4)  
Completeness (%)  99.5 (100)  95.9 (100)  
Multiplicity  5.9 (6.0)  3.1 (2.9)  
Rmerge (%)  3.9 (17.4)  6.1 (51.9)  
Rmeas  (%)  4.3 (19.1)  7.3 (62.7)  
Rpim (%)  1.8 (7.8)  3.9 (34.7)  
Refinement    
Rfactor/Rfree (%)  18.68/22.98  20.1/27.2 
Protein Atoms  1257  1258  
Ligand atoms  12  -  
Water molecules   66 23  
R.m.s.d. bonds (Å)      0.008        0.009 
   R.m.s.d. angles (°)   1.053  1.30  
Average B (Å2)  
   Protein  41.5  57.8  
   Solvent  42  53.5  
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MtOGT-Y139F structure analysis. 
  
As mentioned in the “Introduction” section, the main exception to the 
otherwise high degree of structural conservation displayed by the 
catalytic C-terminal domain of MtOGT is represented by the 
conformation adopted by the active site loop, (residues from 136 to 141), 
(Figure 5). 
 
Figure 5 
 
 
 
 
 
 
 
 
 
 
 
The active site loop of MtOGT is observed in a new conformation. Close-up view 
of equivalent regions of MtOGT (in green; pdb:4BHB) (18) and human AGT in the 
absence of ligands (in magenta; pdb:1EH6). 
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In fact, in all crystal structures of OGT/AGT of other species reported 
until now, this element is observed in a “pointing inwards” conformation 
that appears functional to narrowing the catalytic pocket. In particular, 
the highly evolutionary conserved tyrosine residue of the active site loop 
(Tyr158 in human AGT) has been suggested to provide an aromatic 
environment for locking the alkyl adduct of the flipped-out modified 
base inside the active site. Of outmost interest, a point-mutated variant 
of human AGT, in which Tyr158 is replaced by a phenylalanine, is only 
slightly less effective than the wild-type AGT in protecting the 
alkyltransferases-lacking E. coli strain GWR109 from MNNG killing 
(34). In sharp contrast, our biochemical analysis revealed that an 
equivalent MtOGT-Y139F variant displays a ten-fold lower affinity for 
the dsDNAmet with respect to the wild-type MtOGT (Table 2), while the 
ability of binding unmodified DNA appears unaltered (Figure 3, panel 
D).  
The analysis of the 2.6-Å resolution crystal structure of MtOGT-Y139F 
(Table 3) does not reveal any structural rearrangement at the level of the 
active site loop C-backbone with respect to the wild type MtOGT 
structure (Figure 6).  Consequently the observed catalytic defect could 
not be imputable to a mere destabilization of local conformation at the 
level of catalytic C-terminal domain.  
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Figure 6 
 
 
 
MtOGT and MtOGT-Y139F active-site loop conformation. Close-up view of 
MtOGT (in green;pdb:4BHB)(18) and MtOGT-Y139F (in grey; present work) C-
terminal domain upon, optimal superposition of the corresponding crystal structures. 
The mutated 139 residues and the catalytic cysteine are rendered as ball and sticks. 
 
 
On the basis of structural comparison analyses to the human AGT in 
complex with methylated dsDNA, we previously showed that Tyr139 in 
MtOGT is correctly oriented to establish a hydrogen bond with the 
phosphodiester group at the 5’ side of the flipped-out modified base 
(Figure 7A) (18). Interestingly, by adopting this unprecedented 
conformation, MtOGT Y139 seems to functionally compensate for the 
absence of an arginine residue at position 116 of the recognition helix 5, 
Y139 
F139 
C126 C126 
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which in human AGT (i.e. Arg135) is engaged in an equivalent contact 
with the DNA sugar-phosphate backbone (Figure 7B).  
Figure 8 illustrates structure-based models of the possible mode of 
binding of unmodified (black) and methylated (magenta) dsDNA to 
MtOGT, showing that the flipping-out of the modified base brings its 5’ 
phosphate group closer to the Tyr139 hydroxyl-group, in order to 
establish a hydrogen bond. 
Taken as a whole, our biochemical and structural characterization of the 
MtOGT-Y139F variant pinpoints Tyr139 as a molecular determinant 
discriminating between unmodified and alkylated DNA substrates 
through a novel mechanism, whose detailed description should await the 
resolution of the crystal structure of MtOGT in complex with DNA.  
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Figure 7 
 
 
 
 
 
 
 
 
 
Solvent exposed conformation of the invariant Tyr139 would not hamper DNA 
binding. (A) Possible mode of binding of methylated guanine bearing dsDNA  to 
MtOGT resulting upon optimal superposition of MtOGT on the structure of a 
Cys145Ser human AGT mutated version in complex with O6-metgylguanine dsDNA 
(pdb:1T38). (B) Schematic of DNA contacts of MtOGT and human AGT. 
Phosphates are labeled in red. Arrows point to contacts between indicated residues 
side chain and DNA sugar-phosphate backbone. 
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Figure 8 
 
Structure based models of MtOGT in complex with DNA substrates. Cartoon 
representation of the possible mode of binding of unmodified DNA (black) and O6-
methylguanine bearing DNA (magenta), upon  optimal superposition of MtOGT 
structure (pdb:4BHB) to that of human AGT in complex with O6-MeG-dsDNA 
(pdb:1T38)  
 
 
 
 
 
 
Y139 
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Conclusions 
 
 
Mycobacterium tuberculosis, the etiologic agent of TB, is an extremely 
well adapted human pathogen surviving and replicating inside the human 
macrophages. During the infectious process, M. tuberculosis is exposed 
to a variety of potentially DNA-damaging assaults including alkylating 
agents that may compromise both the persistence in the host’s infected 
macrophages and the reactivation of the bacillus from the dormant state. 
Accordingly, DNA repair pathways are crucial in maintaining genome 
integrity as well as a low level of genetic variability. M. tuberculosis 
counteracts the effect of DNA alkylation either by using multi-step 
repair systems or by direct removal of the alkyl group from the damaged 
base performed by DNA-protein alkyltransferases such as the “suicidal” 
O6-methylguanine DNA methyltransferase (OGT). Since a number of 
broadly geographically distributed M. tuberculosis strains show 
nonsynonymous single-nucleotide polymorphisms (nsSNPs) in their ogt 
gene, it was supposed a possible contribution of corresponding mutated 
OGT to the success of this strains in terms of adaptation to the human 
host. Detected nsSNPs map at the region of the gene encoding the poorly 
functionally characterized N-terminal domain of the protein, and result 
in threonine 15 and arginine 37 substituted by serine and leucine, 
respectively. 
In the present work we report the structural and biochemical 
characterization of wild type M. tuberculosis OGT (MtOGT) and of the 
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MtOGT-T15S and MtOGT-R37L mutated proteins, revealing that the 
R37L variant is characterized by a ten-fold lower affinity for alkylated 
double stranded DNA than the wild type enzyme. These results provided 
experimental evidence to a possible contribution of this SNP to the 
“mutator” phenotype proposed for the corresponding widely distributed 
strains. 
MtOGT crystal structure analysis revealed an element of novelty when 
compared to other ligand-free or DNA-bound OGT structures: The C-
terminal active site loop adopts an unprecedented conformation 
exposing the invariant Tyrosine 139 to the bulk solvent.   
Further biochemical investigations on structure-based designed MtOGT 
point-mutated variants (i.e. MtOGT-R37K, MtOGT-R37E and MtOGT-
Y139F) provided new insights in the molecular mechanisms adopted by 
the analysed residues in coordinating the catalytic cycle. In particular, 
we showed that a positively charged residue at position 37 is required 
for an optimal DNA binding activity and that the conserved tyrosine 
residue at position 139 can possibly establish a hydrogen bond with 
alkylated-DNA through its hydroxyl group, a feature never observed for 
OGTs from other species. Confirmation of such a proposal, together with 
a complete mechanistic overview of the MtOGT damaged-DNA 
recognition and repair, will be provided by our ongoing investigations 
on the crystal structure of MtOGT in complex with alkylated double 
stranded DNA.  
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Overall, our in vitro biochemical and structural studies on mycobacterial 
OGT contributed to better understand DNA-direct repair in 
Mycobacterium tuberculosis. 
The future activity for this research project will focus on the study of 
protein-protein and protein-DNA interactions involving MtOGT and 
other key enzymes of DNA-repair pathways, to possibly disclose cross-
talks between different DNA repair systems in M. tuberculosis.  
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